Real Time Modulation of End Diastolic Volume as a Novel Therapy for Dilated Cardiomyopathy and Congestive Heart Failure by Biswas, Saurabh
  
REAL TIME MODULATION OF END DIASTOLIC VOLUME AS                        
A NOVEL THERAPY FOR                                                                                     
DILATED CARDIOMYOPATHY AND CONGESTIVE HEART FAILURE   
 
 
A Dissertation 
by 
SAURABH BISWAS 
 
 
Submitted to the Office of Graduate Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of  
DOCTOR OF PHILOSOPHY 
 
 
May 2011 
 
 
Major Subject: Biomedical Engineering 
  
  
REAL TIME MODULATION OF END DIASTOLIC VOLUME AS                                   
A NOVEL THERAPY FOR                                                                                        
DILATED CARDIOMYOPATHY AND CONGESTIVE HEART FAILURE   
 
A Dissertation 
by 
SAURABH BISWAS 
 
Submitted to the Office of Graduate Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of  
DOCTOR OF PHILOSOPHY 
 
Approved by: 
Chair of Committee,  John C. Criscione 
Committee Members, Fred Clubb 
 William A. Hyman 
 Duncan J. Maitland 
                                          Matthew W. Miller 
Head of Department, Gerard L. Cote 
 
 
 
May 2011 
 
Major Subject: Biomedical Engineering 
iii 
 
ABSTRACT 
 
Real Time Modulation of End Diastolic Volume as a Novel Therapy for Dilated 
Cardiomyopathy and Congestive Heart Failure.  (May 2011) 
Saurabh Biswas, B.Sc.,University of Calcutta; M.Sc.,Birla Institute of Technology;  
M.S., University of Toledo 
Chair of Advisory Committee: Dr. John C. Criscione 
 
Congestive heart failure (CHF) is a major public health issue in the developed and 
developing world. In the U.S., CHF affects more than 5.3 million people with 550,000 
new cases diagnosed each year. Approximately 20% of hospitalizations are due to acute 
CHF, incurring a health-care system cost of $34.4 billion. Heart failure has two main 
forms: systolic dysfunction and diastolic dysfunction. Many patients with heart failure 
have both types of dysfunction. Though systolic heart failure is more commonly 
mentioned, there is growing recognition that CHF caused by a predominant abnormality 
in diastolic mechanics (filling and relaxation) causes significant morbidity and mortality. 
In patients with systolic heart failure, there are abnormalities in the pressure-volume 
relationship during systole that includes decreased ejection fraction (EF), stroke volume, 
and stroke work. In patients with isolated diastolic heart failure, the only abnormality in 
the pressure-volume relationship occurs during diastole, when there are increased 
diastolic pressures with normal diastolic volumes. Whereas the diastolic pressure-
volume relationship may reflect a more compliant chamber, increased diastolic pressure 
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and abnormal relaxation reflect the presence of abnormal diastolic function. Therefore, 
patients with symptomatic heart failure have abnormalities in diastolic function, those 
with a normal EF have isolated diastolic heart failure, and those with a decreased EF 
have combined systolic and diastolic heart failure. Thus a critical gap in present device 
solutions to CHF is a single device that can address concurrently reduction of LV 
chamber dimensions (remodeling) and also improve and not impede LV filling by 
lowering the filling pressure (i.e. without impeding diastolic function).  
 
The biphasic support and recoil device technology investigated in this dissertation would 
provide a means for guided intervention whereby normal growth and remodeling 
processes are directed toward a gradual reduction in size in systolic dysfunction and 
enhanced ventricular filling using diastolic recoil properties of the device. In this 
dissertation prototyping and testing of a novel minimally invasive cardiac device 
technology is presented. Our tests indicate that this technology has the necessary 
mechanical actions to enable the integration of therapy for systolic and diastolic 
dysfunction in two principal ways (1) adjustable passive cardiac support or progressive 
constraint to facilitate the gradual reduction in size of dilated, diseased hearts, thereby 
improving pumping efficiency; (2) diastolic recoil technology with the ability to transfer 
energy from systolic contraction to diastolic filling, which may potentially reduce 
ventricular filling pressures, without compromising ventricular systolic function. 
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CHAPTER I 
  
INTRODUCTION: CONGESTIVE HEART FAILURE 
 
Congestive heart failure (CHF) is a debilitating condition being responsible for over 
20% of all hospital admissions today among persons older
 
than 65 years of age with an
 
incidence approaching 10 per 1000 population. Though multiple drugs and devices are 
commercially available to clinicians and surgeons today to address CHF, considerable 
efforts are still underway to find a solution that is more than a maintenance therapy. 
Heart transplantation is the ideal solution for these patients with end stage heart failure 
but there are approximately 3000 hearts annually available with hundreds of thousands 
in need of transplant on waiting list and millions of patients progressing towards a 
condition where they would need a transplant. Thus other than present pharmaceutical 
approaches a more viable device solution is needed to address this epidemic. In last two 
to three decades left ventricular assist devices have provided a lot of hope to these 
patients but challenges have remained in terms of quality of life issues and complex post 
implantation infections and complications mostly due to blood contacting nature of the 
device. 
 
 
 
 
 
 
____________ 
This dissertation follows the style of the Journal of Medical Devices. 
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Objectives 
Cardiac support devices (CSD) are one of the new classes of devices that have evolved 
over last two decades with a theoretical foundation in Laplace law. CSD‘s are non-blood 
contacting and have exhibited safety in the clinical trials conducted over last decade but 
questions still remain of their efficacy because of some fundamental drawbacks in the 
design and clinical efficacy. Although CSD‘s have shown to be effective, significant 
problems remain and it is the goal of this dissertation to advance the technology of 
cardiac support. The objectives and the problems addressed are discussed in Table 1. 
 
Table 1 Objectives and problems addressed in this dissertation  
 
 
 Objectives 
                                                                                 
Problems Addressed 
 
1. Prototype and test in vivo and 
in-vitro cardiac support device 
which can be adjusted post 
implantation with progressive 
remodeling of the heart.   
 
Adjustability post implantation: Non-adjustable 
nature of present cardiac support devices prevents 
any management of the device post implantation. 
With remodeling the device loses its girdling 
effect on the myocardium limiting device action to 
heart sizes at time of implant. 
 
 
2. Prototype and test in-vitro an 
implantable device which 
would enhance the ventricular 
filling by utilizing recoil 
effect.  
 
 
Impaired ventricular filling: Present devices 
because of its girdling effect on the ventricles 
reduce the ventricular filling by stiffening the 
ventricular wall, potentially leading to high atrial 
pressures. 
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Table 1 continued 
 
 Objectives 
                                                                                 
Problems Addressed 
 
3. Prototype and test in-vitro combined 
biphasic support and recoil device to 
fully modulate diastolic mechanics.  
  
As mentioned in objectives 1 and 2, 
combined device would address in a single 
integrated design the problems of both 
adjustability with present CSD‘s and also 
impaired ventricular filling in failing 
hearts.  
 
 
4. Prototype a device which can 
significantly reduce pericardial 
adhesion post implantation and can be 
adjusted in size with anatomical 
changes of cardiac size for pediatric 
and adult patients.  
 
Pericardial adhesion:  Present cardiac 
support devices which are either made of 
polymer meshes or nitinol get attached to 
the myocardium through universal 
presence of adhesions between the heart 
and the mediastinal structures including 
the sternum, which increases the difficulty 
and potentially the risks of the procedure if 
there are any needs of repeat surgery. Also 
the constricting nature of the adhesions 
also prevents the natural cardiac motion, 
potentially leading to aberrant mechanics 
being induced during the recovery process. 
 
Also in pediatric patients with congenital 
heart defects where redo surgeries are 
needed. There are limited alternatives in 
terms of FDA approved solutions which 
mitigate adhesion formation where 
procedures through a median sternotomy 
become less complicated.  
 
 
4 
 
Background 
Congestive heart failure (CHF) is a major public health issue in the developed and 
developing world. In the U.S., CHF affects more than 5.7 million people with 550,000 
new cases diagnosed each year. Approximately 20% of hospitalizations are due to acute 
CHF, incurring a health-care system cost of $37.2 billion [1]. Heart failure has two main 
forms based on dysfunctions in either pumping or filling phase of cardiac cycle. One of 
the forms, systolic dysfunction, occurs when there is an abnormality in the ejection phase 
(i.e. ejection fraction reduced) the second form diastolic dysfunction occurs when there 
is abnormality in filling of the ventricle with a normal ejection fraction. Some patients 
with end stage heart failure have both types of dysfunction. In systolic dysfunction, the 
heart contracts less forcefully and cannot pump out as much of the blood that is returned 
to it as it normally does. As a result, more blood remains in the lower chambers of the 
heart (ventricles). In diastolic dysfunction, the heart is stiff and does not relax normally 
after contracting, which impairs its ability to fill with blood. The heart contracts 
normally, but is unable to pump a normal proportion of blood out of the ventricles 
because filling is sub-optimal. Often, both forms of heart failure (systolic and diastolic) 
occur together. Although systolic heart failure is more commonly mentioned, there is 
growing recognition that congestive heart failure (CHF)
 
is caused by a predominant 
abnormality in diastolic function. 
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Figure 1. Coronary artery disease being the initial problem leads to an index event like acute 
myocardial infarction (Heart attack) which can be the starting point of congestive heart failure. 
 
 
 
 
Heart failure is a progressive disorder which can be initiated by multiple cardiac index 
events like acute myocardial infarction, as shown in Figure 1,  whereby the 
hemodynamic and symptomatic states of the patient worsen over time causing 
irreversible damage despite the absence of clinically apparent adverse events [2- 4]. 
Coronary artery disease causes approximately 70% of congestive heart failure. Acute 
myocardial infarction (AMI) due to obstruction of a coronary artery is the most common 
initiating event that can lead ultimately to heart failure. The symptomatic deterioration 
over a period of a time after the initial recovery period of AMI is accompanied by 
progressive left ventricular (LV) chamber remodeling or also referred to as cardiac 
remodeling [4-6]. LV remodeling is a progressive phenomenon characterized globally by 
changes in LV chamber size and shape and with implications at the cellular level, by 
ongoing loss of cardiomyocytes, myocyte hypertrophy and interstitial fibrosis [5]. The 
Congestive 
Heart failure 
(Class I – IV) 
Coronary 
Artery 
Disease 
Device options: 
Balloon 
Angioplasty, 
Bare metal & 
Drug Eluting 
Stents, 
Coronary 
Artery Bypass 
Grafting 
Very limited 
device options to 
reverse the disease 
progression 
Myocardial 
Infarction 
(Heart Attack) 
 
Present Device Approaches: Lack of 
Early stage intervention options as 
present devices are implanted post 6 
months.  
3-6 months:  
Post heart 
attack 
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important determinants of LV dysfunction and subsequent remodeling are myocyte loss, 
hypertrophy and accumulation of collagen in the interstitial compartment [5, 6]. The 
progressive remodeling leads to basically three broad class of ventricular dysfunction in 
most patient populations. 
1. In patients with systolic heart failure two major changes are seen: 
 Altered ventricular contraction 
 Inability to empty 
In patients systolic heart failure usually develops because the heart cannot contract 
normally. It may fill with blood, but it cannot pump out as much of the blood it contains 
because the muscle is weaker. As a result, the amount of blood pumped to the body and 
to the lungs is reduced, and the ventricle, usually enlarges.  There are abnormalities in 
the pressure-volume relationship during systole, which includes decreased EF, stroke 
volume, and stroke work.  
2. In patients with diastolic heart failure two major changes are seen: 
 Altered ventricular relaxation 
 Inability to fill 
Diastolic heart failure can occur alone or in combination with systolic heart failure. In 
patients with isolated diastolic heart failure, the only abnormality in the pressure-volume 
relationship occurs during diastole, when there are increased diastolic pressures with 
normal diastolic volumes. When diastolic pressure is markedly elevated, patients are 
symptomatic at rest or with minimal exertion (NYHA class III to IV). With treatment, 
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diastolic volume and pressure can be reduced, and the patient becomes less symptomatic 
(NYHA class II), but the diastolic pressure-volume relationship remains abnormal.  
3.   Another form is combined systolic and diastolic heart failure. Patients may have 
only a modest decrease in ejection fraction (EF) and a modest increase in end-
diastolic volume but a marked increase in end-diastolic pressure and a diastolic 
pressure-volume relationship that reflects decreased chamber compliance. Given that 
all patients with symptomatic heart failure potentially have elevated end-diastolic 
pressures, diastolic function is abnormal in all patients. Patients with a normal EF 
have isolated diastolic heart failure, and those with a decreased EF likely have 
combined systolic and diastolic heart failure. 
 
Left ventricular remodeling: Mechanism for heart failure progression  
The role of LV remodeling in heart failure is still under active debate as some 
investigators currently view LV remodeling simply as the end-organ response that 
occurs following years of exposure to the deleterious effects of long-term 
neurohormonal stimulation, but with clinical outcomes studies and understanding of the 
basic mechanism there is increasing evidence that LV remodeling may contribute 
independently to the progression of heart failure [7, 8]. Considering the complexity of 
the LV remodeling process, a number of changes occur during the process of LV 
remodeling and directly contribute to worsening heart failure. One of the most 
significant observations with respect to the abnormal geometry of remodeled ventricle 
was the consistent finding that the remodeled heart was not only larger, but was also 
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more spherical shape [9]. The events that lead to LV remodeling are numerous. As the 
load on the ventricle at end diastole contributes importantly to the afterload that the 
ventricle faces at the onset of systole, any dilation of the LV will increase the work of 
the ventricle leading to increased oxygen utilization. Apart from the increase in LV end-
diastolic volume with LV remodeling wall thinning also occurs. Thus increase in wall 
thinning along with the increase in afterload created by LV dilation leads to a functional 
―afterload mismatch‖ that may further contribute to a decrease in forward cardiac output 
[10-13]. 
 
This LV remodeling becomes a cause of onset of a positive feedback loop, leading to 
acute dysfunctional cardiac pumping with worsening neurohormonal activation and 
inability of the remodeled LV to respond appropriately to these compensatory 
mechanisms.  This in turn leads to a stage where the aggregate end-organ changes that 
occur within the cardiomyopathic ventricle may progress to the point that no amount of 
neurohormonal stimulation can maintain cardiovascular homeostasis, at which point 
heart failure may progress independent of the neurohormonal status. Given this strong 
role of LV remodeling in promoting a maladaptive cardiac geometry, preventing or 
reversing remodeling has emerged as an important target in the treatment of CHF [14]. 
As the disease progresses there is a change in the shape of the ventricle from a prolate 
ellipse to a more spherically shaped ventricle. This transformation from elliptical to 
spherical shape and associated functional changes are directly related to future 
deterioration in LV performance and less favorable clinical outcomes in patients with 
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heart failure. Clinical data provides increasing evidence that LV remodeling can 
contribute to the progression of heart failure by virtue of the de novo mechanical and 
energetic burdens that are created by the physiologically unfavorable changes that occur 
in the remodeled ventricle.  
 
Stress & strain: Key biomechanical factors in left ventricular remodeling 
The heart is a biomechanical pump, and the important pillars of biomechanics: force 
(stress) and motion (strain) play a fundamental role in the mechanobiology and 
development of physiological and pathological states. The understanding of the 
influence of mechanical stimuli on biological processes such as growth and remodeling 
is at a very early stage and should be further investigated in order to better define 
effective treatments for cardiovascular disease. 
  
In the remodeling process, the left ventricle (LV) undergoes a transformation from 
prolate ellipsoid to a more spherical shape resulting in an increase in meridional wall 
stress of the LV, which in turn creates a number of de novo mechanical burdens for the 
failing heart. Progressive LV dilation and subsequent remodeling is one of the 
mechanisms that leads to LV wall stress and myocardial stretch [15, 16]. The imbalance 
of the normal stress pattern triggers increased myocardial oxygen consumption and 
myocardial stretch, activating stretch-response proteins that may play an important role 
in the development of maladaptive cardiomyocyte hypertrophy [17]. LV dilation and 
increased LV sphericity are also sensitive indicators of poor long-term outcome [18, 19]. 
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Thus, cardiac wall stress, which can be defined as the force acting per unit of cross-
sectional area of the ventricular wall, is directly related to pressure in the ventricles and 
ventricular radius, and inversely related to ventricular wall thickness [20]. 
  
Cardiac wall stress can be related to the ratio of the product of pressure in the ventricles 
and ventricular radius, to the ventricular wall thickness. So with LV remodeling and an 
increase in ventricular volumes and a subsequent increase in ventricular radius, a larger 
force is required from each individual myocyte to produce enough pressure in the 
ventricles, thus wall tension is seen as a function of both internal pressure and vessel 
radius. Also with ventricular remodeling, cardiac mass can increase, with associated 
changes resulting in ventricular wall thickness. Any such thickness increase would result 
from remodeling at the cellular/extracellular matrix level by several processes including 
myocyte hypertrophy, cell slippage, and interstitial growth. However, such a wall 
thickness increase does not adequately compensate for the increase in wall stress 
resulting from cardiac chamber dilation with an increasing metabolic stress. Thus, 
ventricular remodeling is maladaptive, despite any potential incremental increase in 
ventricular wall thickness.  
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Biomechanical model of heart failure 
In the last few decades several different clinical model
 
systems, including a cardiorenal 
model, a hemodynamic model,
 
and a neurohormonal model have been applied to 
understand the fundamental mechanisms and therapeutic approaches in treating the 
problem. Each of these models has
 
strengths and weaknesses in terms of understanding 
the mechanisms
 
responsible for heart failure and developing effective new therapies. 
Initially, CHF was seen as a problem of excessive
 
salt and water retention that was 
caused by abnormalities of
 renal blood flow also known as the ―cardiorenal model‖ [21]. 
Better quantification of hemodynamic parameters by clinicians led to an understanding 
that heart failure was associated with a reduced cardiac
 
output and excessive peripheral 
vasoconstriction and led to the development of the ―cardiocirculatory‖ or 
―hemodynamic‖ model [21] for heart failure. Thus, although the cardiorenal models 
provided the rational basis for the use of diuretics
 
to control the volume status of patients 
with heart failure,
 
and the cardiocirculatory model provided the rational basis
 
for the use 
of inotropes and intravenous vasodilators to augment
 
cardiac output, these therapeutic 
strategies have not prevented
 
heart failure from progressing, nor have they led to 
prolonged
 
life for patients with moderate to severe heart failure [21, 22]. 
 
The advent of ACE inhibitors and beta blockers has dramatically changed the way in 
which
 
we conceptualize heart failure. Various studies and clinical trials have provided 
data and have led to both experimental model systems and clinical
 
trials which suggest 
that both types of therapy may prevent the progression
 
of pump dysfunction that 
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characterizes the natural history of
 
heart failure and may halt or even reverse the 
progressive cardiac
 
dilatation that occurs as heart failure progresses. These observations 
have led to a point of view that heart failure should be viewed as
 a ―neurohormonal 
model‖ in which heart failure progresses as a result of the overexpression of biologically 
active molecules
 
that are capable of exerting deleterious effects on the heart
 
and 
circulation [23]. Although these three models explained some of the mechanistic aspects 
and disease symptoms in the heart failure patients, none of
 
these models explain the 
relentless "disease progression"
 
that occurs in this syndrome.  
 
With increasing evidence of the relationship and importance of the interaction
 
between 
myocardial systolic dysfunction and cardiac remodeling
 
in the development and 
progression of heart failure, these observations suggest that
 
heart failure can be viewed 
as a ―biomechanical model‖ [8], in which heart failure develops and progresses as a 
result of the deleterious
 
changes in cardiac function and cardiac remodeling that occur
 
as 
the result of sustained neurohormonal activation. This model provides a new insight into 
the way the problem is approached but does not obviate the importance of the 
cardiorenal and hemodynamic models, and neurohormonal
 
activation in the onset of 
heart failure. It extends the insights
 
provided by this paradigm by focusing the treatment 
of heart
 
failure on the downstream biological consequences of neurohormonal
 
activation 
rather than on neurohormonal activation per se. Thus, future therapies should be targeted 
more at alleviating the adverse biological consequences of neurohormonal activation 
along with the treatment of the patient symptoms with diuretics and digitalis. A key 
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aspect of the biomechanical model described by Mann et al is the explanation of the 
resistance to optimal therapy in end stage patients. One important departure of the 
biomechanical model from the
 
neurohormonal model is that the biomechanical predicts 
that
 
at some point heart failure will progress independently of the
 
neurohormonal status 
of the patients. Thus, when the deleterious
 
changes in cardiac function and cardiac 
remodeling are sufficiently
 
advanced, they become self-sustaining and hence are capable
 
of driving disease progression independently of the neurohormonal
 
status of the patient. 
This may help to explain, at least in
 
part, why conventional neurohormonal strategies 
lose effectiveness
 
in end-stage heart failure [24] as well as why many device-based
 
therapies that concurrently affect LV pump performance and LV
 
remodeling (e.g., 
cardiac resynchronization) are beneficial [8].  
 
Conventional treatments for diastolic and systolic heart failure 
For treating systolic heart failure there are several classes of solutions, e.g. 
pharmaceuticals, stem cells, electrical devices, mechanical devices, and surgical 
reconstruction. Each of these are designed for some limited target action (i.e., beta-
blockade, ACE inhibition, electrical pacing, cardiac assist, etc); consequently, heart  
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failure remains a cause of tremendous morbidity and healthcare burden. Conventional 
approaches fail to address the possibility that mechanical stimuli are important 
parameters for guiding growth and remodeling, processes that may ultimately facilitate 
the recovery of mechanical organs.  
 
The mechanical heart assist devices targeted to systolic heart failure are classified into 
active devices that provide pumping energy, and passive devices that modulate the shape 
of the heart. The active devices are subdivided into blood pumps (such as the DeBakey, 
Jarvik, Heart Mate), counter pulsation assist devices (aortic balloon pumps), and direct 
cardiac compression devices or DCCDs (Anstadt cup, Abio Booster). The passive, 
―support‖ devices (Cor-cap, Heartnet, Myosplint, etc.) directly interact with the heart to 
change shape or limit growth. Diastolic heart failure therapies presently include mostly 
pharmaceutical products and there are few, if any, devices available. There are presently 
no approved devices for treatment of the DHF symptoms. However, two preclinical 
stage recoil device concepts, LEVRAM and Imcardia (Corassist Inc) have a potential 
role in the treatment of DHF patients.   Table 2 summarizes the present devices either 
approved by FDA or under development for treating congestive heart failure therapy. 
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Table 2 Present landscape of cardiac devices in congestive heart failure therapy          
 
Disease 
State 
 
 
Present Device  
Solutions 
 
Drawback of present FDA approved 
solutions 
 
Systolic 
heart 
failure 
 
• LVADS 
• Biventricular pacemakers 
• CorCap & HeartNet 
(passive devices clinical 
trials) 
 
 
Surgical complications with implantation 
of LVAD‘s as most require open heart 
surgery and post surgical patient 
management complexities 
 
Clinical efficacy of biventricular 
pacemakers questioned in patients with 
dilated cardiomyopathy and atrial 
fibrillation 
 
LVAD‘s are expensive as average cost is 
around $65000 and post surgical costs 
are higher 
 
Therapies approved for end stage 
patients: Very few options for early stage 
heart failure patients 
 
Present pharmaceutical options are also 
maintenance therapies 
 
Diastolic 
heart 
Failure 
 
 
• Presently no FDA 
approved devices 
• Imcardia & LEVRAM : 
preclinical stage devices 
 
 
 
 
Cardiac 
resuscitation 
& 
Post- 
Cardiotomy 
 
• Counter-pulsation 
devices (IABP) 
• Single or biventricular 
support devices 
• Myovad: preclinical stage 
device 
        
Regenerative therapies incorporating stem cells have demonstrated potential but have yet 
to be fully developed. Benefits observed in stem cell studies have been controversial, 
e.g. there is a general lack of evidence that implanted stem cells are actually integrating 
with the native tissue as functional cardiomyocytes [25-28]. Stem cells are typically 
transplanted into the diseased myocardium where fiber alignment is highly disorganized 
and disrupted by fibrotic tissue. An advanced understanding of the stress and strain 
perturbations will be important for the future development of therapeutic and device 
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approaches involving surgical and catheter interventional treatments like passive 
ventricular constraint Corcap, Coapsys, Surgical Anterior Ventricular Restoration 
(SAVR), Dor, Fontan stitch, papillary muscle sling, Menicanti tri-level LV repair, 
coronary sinus cerclage, etc which are aimed at reversing deleterious LV remodeling. 
Although many devices are under development or FDA approved for treating patients 
with end stage heart failure there is a large unmet need for a device which can fully 
modulate the diastolic mechanics in a minimally invasive manner. Novel, minimally 
invasive devices and surgical strategies designed to reverse the LV remodeling by 
modulating the stress and strain abnormalities concurrently may be a new paradigm and 
a solution towards preventing the progression of global LV systolic and diastolic 
dysfunction. The research presented in the following chapters has been motivated 
predominantly by this concept.  
  
In CHAPTER II, a central issue of ventricular remodeling i.e. progressively enlarging 
left ventricular size is addressed. Discussed is the development of a passive support 
device with a fundamental design innovation by introducing adjustability of passive 
chambers to modulate end diastolic volume in real time. Other clinically advantageous 
features like intrinsic pneumatic attachment negating the need to suture the device to 
heart, non-blood contacting and non- fibrotic bilayered design have been incorporated. 
This device would also be applicable to other structural heart diseases like idiopathic 
dilated cardiomyopathy, hypertrophic cardiomyopathy and viral cardiomyopathy. The 
device has been prototyped and implanted in an acute ovine model where the 
17 
 
implantability, attachment and ability to modulate end diastolic pressure volume 
relationship was tested using both air and saline to adjust the device size. 
 
In CHAPTER III, another aspect of heart failure which is abnormal ventricular filling is 
being addressed with the design of a diastolic recoil device based on the same platform 
of passive support device but with key design improvisations. The diastolic recoil device 
being prototyped is designed for clinical conditions like diastolic dysfunction, mitral 
valve regurgitation or diastolic heart failure. During diastolic phase of cardiac cycle the 
myocardial relaxation occurs leading to filling of ventricles with blood and this process 
is altered in patients with diastolic dysfunction. In addition to active and passive 
properties of the myocardium, geometrical characteristics of the chamber and external 
forces play an important role in the modulation of diastolic mechanics. This device is the 
first device designed to be implanted minimally invasively and enhance myocardial 
recoil during diastole leading to ventricular filling at lower pressure. The device design 
was prototyped and bench-top tested with use of a mock heart model. 
 
In CHAPTER IV, the goal is to develop a device which can address both ventricular 
remodeling and filling problems in end stage heart failure patients in a minimally 
invasive approach. The proposed combined Biphasic support and recoil device is a 
significant innovation in heart failure device space, as it is a fully implantable device 
which can address the issue of cardiac support (passive constraint) and diastolic recoil in 
a single integrated design. This design incorporates both design features from 
18 
 
CHAPTERS III & IV and provide a single platform where multiple etiologies can be 
treated using a single device. 
 
In CHAPTER V, we discuss a novel approach for prevention of pericardial adhesion 
post cardiothoracic surgery. One of the challenges in pediatric cardiothoracic surgeries 
which require multiple interventions is the change in anatomical dimensions of the heart 
with age as some surgeries need to be performed over a multiple year timeframe. The 
adjustable design of the device we have developed here is expected to provide the 
benefit of changing the device size with changing cardiac dimensions of the patient. 
Also the bilayered nature of the device provides the surgical plane to access the 
pericardium to the surgeon during the surgical intervention. We discuss the novel 
features of this device and its utility in this novel anti-pericardial device adhesion space  
 
Thus utilizing our proposed device platform we intend to develop an integrated approach 
towards modulation of end diastolic volume in a minimally invasive manner. Present 
solutions are too invasive and do not improve the quality of life of the patients. We 
hypothesize that the combined passive girdling and diastolic recoil effect of the device  
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will prevent LV dilatation and sphericalization by positively impacting the stress 
patterns along with enhanced filling of the ventricles thereby lowering the left atrial 
pressure. Moreover, once normal cardiac kinematics is restored pharmacotherapy should 
be directed towards preventing the return of aberrant motions. We believe our results 
enable future investigations and will lead to more advanced and in-depth understanding 
of key biomechanical factors, mechanisms and interactive role of pathophysiological 
forces which lead to irreversible remodeling and myocardial damage and subsequent 
resistance to optimal drug therapy in millions of patients with end stage heart failure. 
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CHAPTER II 
 
DEVELOPMENT OF A NOVEL CARDIAC SUPPORT DEVICE                                   
TO REDUCE VENTRICULAR DILATATION 
 
Introduction 
Heart failure typically begins after an ―index event‖ leading to an initial decline in 
pumping capacity of the heart. Following this initial decline in pumping capacity, a 
variety of compensatory mechanisms are activated which with time trigger left 
ventricular (LV) remodeling and subsequent cardiac decompensation. As a consequence 
of resultant worsening LV remodeling and cardiac decompensation, patients undergo a 
transition from asymptomatic to symptomatic heart failure. To reverse this progressive 
disorder cardiac support devices have been of great clinical interest over the last two 
decades to intervene in the remodeling process and prevent the resulting ventricular 
dilatation. 
  
Study Goals                
With an understanding of the present state of the art in cardiac support devices and 
prominent role of geometric and mechanical factors in driving the remodeling associated 
with disease progression, an implantable device has been prototyped and tested which 
can be adjusted post implantation to reverse remodel the heart i.e. reduce heart size. 
Nitinol and polymer based support devices are under development and are presently in 
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clinical trials but these devices cannot be adjusted post implantation with the progressive 
remodeling of the heart. A novel device has been conceptualized to mitigate the present 
challenges of the support devices.  
 
To advance the feasibility of the concept and the device design we have four important 
goals:  
1. Prototyping of the device 
2. Testing of the prototype in bench-top mock heart model 
3. Testing of the prototype in vivo implanted through sternotomy 
4. Testing of the prototype in vivo implanted through minimally invasive sub-xiphoid 
incision 
 
The details of each goal are: 
1. Prototyping of the device:  Constructing a working prototype of a cardiac support 
device that is adjustable post implantation and implantable through a small one inch 
incision.  
2. Testing of the prototype in bench-top mock heart model: Test the device in a bench-
top experiment to assess the following:  
 End diastolic pressure volume relationship (EDPVR) of Passive 
Constraint/Support with fluid (water) to adjust the passive chambers  
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3. Testing of a prototype in vivo in an ovine model through sternotomy:  In this study 
the device was implanted through sternotomy and the passive chambers where filled 
with air. The goal was to assess the following:  
 Successful implantation of the adjustable cardiac support device 
 Intrinsic pneumatic attachment 
 End diastolic pressure volume relationship (EDPVR) of Passive 
Constraint/Support with air to adjust the passive chambers 
4. Testing of a prototype in vivo in an ovine model through sub-xiphoid implantation in 
a minimally invasive manner:  In this study the device was implanted in a minimally 
invasive manner and passive chambers were filled with saline. In the both studies 
goal was to assess the following:  
 Successful implantation of the adjustable cardiac support device 
 Intrinsic pneumatic attachment 
 End diastolic pressure volume relationship (EDPVR) of Passive 
Constraint/Support with saline to adjust the passive chambers 
Background 
The active and passive chamber properties play a significant role in the understanding of 
physiological and patho-physiological aspects of the cardiovascular system. The left 
ventricular systolic and diastolic pump properties
 
are fundamental to advancing the 
understanding of cardiovascular
 
pathophysiology and therapeutics, especially for heart 
failure. 
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P-V loop analysis and ventricular mechanics 
In last two decades the end-systolic and end-diastolic
 
pressure-volume relationships 
(ESPVR and EDPVR, respectively)
 
have emerged as a meaningful and useful way of 
characterizing intrinsic ventricular
 
pump properties. Furthermore, the physiological
 
significance of the ESPVR and EDPVR was reinforced by their
 
deterministic link to 
myocardial energy demand. Because
 
of the general applicability of the concepts to hearts 
of all
 
species, pressure-volume analysis has become standard in studies
 
of mice, humans, 
and animals of all sizes in between. Once a definition of end-systole (elastance max) and 
end-diastole is chosen, then for a given cardiac cycle, there is a single pressure-volume
 
point that coincides with end diastole and a single pressure-volume
 
point that coincides 
with end systole. If an intervention is performed
 
that acutely changes the loading 
conditions on the heart but
 
has no effect on myocardial contractility (e.g., transient
 
inferior vena caval occlusion to reduce preload, administration
 
of phenylephrine to 
increase afterload, etc.) a family of loops
 
is obtained. The end-systolic and end-diastolic
 
points of these loops delineate two distinct boundaries. The
 
EDPVR, constructed by 
connecting the end-diastolic pressure-volume
 
points of each loop, is nonlinear and 
defines the passive physical
 
properties of the chamber with the muscles in their most 
relaxed
 
state. The ESPVR, constructed by connecting the end-systolic
 
pressure-volume 
points of each loop, defines a reasonably linear
 
relationship that characterizes properties 
of the chamber with
 
the muscles in a state of maximal activation at a given contractile
 
state. 
 
24 
 
Assessment of systolic properties: Ventricular chamber properties depend on myocardial 
properties,
 
muscle mass, and geometry. When mass and geometry are fixed,
 
a shift of the 
ESPVR unambiguously signifies change in intrinsic
 
myocardial contractility. Such 
observations would be typical,
 
for example, of those observed during acute experiments 
in which
 
inotropic agents (positive or negative) are administered. In the setting of 
chronic disease, however, geometry
 
and muscle mass change. Important examples of this 
include the
 
development of the eccentric hypertrophy in dilated cardiomyopathies
 
and 
development of the concentric hypertrophy in idiopathic
 
hypertrophic cardiomyopathy. 
In these cases, determination of
 
the relative degree to which changes in the ESPVR 
reflect changes
 
in chamber properties and changes in muscle properties is complex,
 
with 
no single accepted standardized approach. 
 
 
 Assessment of diastolic properties: The EDPVR is intrinsically nonlinear, a 
characteristic
 
attributed to the different types of structural fibers being
 
stretched in 
different pressure-volume ranges. In the low
 
pressure-volume range, where there is only 
a small increase
 
in pressure for a given increment in volume, compliant elastin
 
fibers and 
myocytes with sarcomeric titin molecules being
 
stretched are believed to account for 
stiffness. As volume is
 
increased further to a higher range, pressure rises more steeply
 
as 
slack lengths of collagen fibers and titin are exceeded and
 
stretch is more strongly 
resisted by these stiff elements. Therefore,
 
chamber stiffness (the change of pressure for 
a given change
 
of volume, dP/dV) increases as end-diastolic pressure (or volume)
 
is 
increased. Shifts of the EDPVR may be reflective of changes in myocardial
 
material 
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properties (e.g., fibrosis, ischemia, edema), physiological
 
remodeling (e.g., as with 
normal growth), or pathological remodeling
 
(e.g., as observed during development of 
hypertrophy and chamber
 
enlargement in heart failure). In all cases, however, the 
EDPVR
 
reflects the net effect of all facets of myocardial material
 
properties, chamber 
structural properties, and extracellular
 
matrix.
  
Theoretical foundation of support devices 
The concept of cardiac support devices in general encompasses passive mechanical 
implants which can resist circumferential expansion of the left ventricle and 
subsequently global cardiac dimensions during diastole, without actively assisting 
contraction during systole. Laplace‘s equation provides a framework for defining means 
of mitigating ventricular remodeling. Using Laplace‘s equation, wall stress can be 
estimated from pressure, chamber size, and wall thickness For a cylinder-shaped 
ventricle: 
T = P × R/h 
 
 
where T = myocardial wall force or wall stress along the cylinder axis, P = left 
ventricular end diastolic pressure, R = chamber radius and h = wall thickness 
 
Ventricular wall stress can be reduced by decreasing transmural pressure, reducing 
cardiac chamber radius, promoting greater ventricular wall thickness, or by some 
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combination of the three. The fundamental role of a passive cardiac support device is 
intended to reduce wall stress by providing counter pressure to the ventricular wall. 
 
                                 Diastolic Wall Stress = Radius x Transmural Pressure  
                                     (Myocyte Stretch)                 Wall Thickness 
 
                  Transmural Pressure = LVEDP – Device pressure directed inwards 
 
Thus, a support device can have a significant impact on effective transmural pressure 
which can lead to a decrease in the wall stress and modulates the end diastolic volume.  
 
Surgical therapies: Dynamic cardiomyoplasty & Batista procedure      
Several surgical device based therapies have been tested in clinical trials and presently 
being implanted in FDA approved trials for
 
mitigating symptoms of heart failure by 
physically remodeling the dilated
 
heart. Stress reduction via Laplace's law is usually 
sited as
 
the rationale for these therapies. The exact mechanisms of role of stress 
reduction and reverse remodeling is yet to be fully understood at molecular, cellular, 
tissue and organ level [28-32]. Consequently, the determination of a clear correlation 
between micro and macro level changes is beyond our current capabilities. 
 
Since the mid 1980's dynamic cardiomyoplasty, has been in practice which involves 
surgically dissecting the patient's latissimus dorsi muscle, introducing it into the thoracic 
cavity, and then wrapping and attaching the muscle to the heart. An implantable 
electrical stimulator is connected to the muscle in order to stimulate and pace it in 
synchrony with the heart. This causes the muscle to contract and also transforms the 
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muscle, making it more fatigue-resistant. The original premise behind dynamic 
cardiomyoplasty was that these muscle contractions, by virtue of the geometry of the 
wrap, would squeeze the heart, and thus provide systolic assistance. The first reported 
clinical case of dynamic cardiomyoplasty using a latissimus dorsi wrap was published in 
1985. Since then, over 1,000 patients have been treated with this experimental 
procedure. Numerous published studies have shown that the procedure produces 
significant improvement in clinical status, as graded by the New York Heart Association 
("NYHA") classification scale, a slight but significant hemodynamic or systolic function 
improvement, and a reduction in the number of patient hospital visits after the procedure. 
However, an improvement in survival has yet to be consistently demonstrated. 
Furthermore, perhaps due to their frail condition, NYHA class IV patients have not fared 
well with the procedure. This has limited its use to NYHA class III patients. It appears 
that the skeletal muscle wrap, probably because of its deterioration over time, does not 
provide sustained squeezing of the heart over time. This lack of efficacy of the surgical 
procedure has led to considerable research into the underlying mechanisms of dynamic 
latissimus dorsi cardiomyoplasty.  
 
Partial left ventriculectomy (PLV), also referred to as the Batista procedure, was 
introduced in 1994 by Brazilian cardiac surgeon Randas Batista to treat patients with 
dilated cardiomyopathy and was first performed in the United States in 1995. The 
procedure was developed to reduce the size and reshape the heart in order to improve 
mechanical function. Batista theorized that resecting a viable section of the lateral left 
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ventricular (LV) wall would reduce LV diameter and, consequently, LV wall stress in 
patients with dilated cardiomyopathy. The procedure consists of resecting the left 
ventricle between both papillary muscles from the apex to the mitral annulus. The 
procedure is usually done in conjunction with mitral valve annuloplasty or replacement, 
although it is sometimes performed alone. Despite initial enthusiasm,
 
clinical studies 
showed that although estimated wall stress
 
was reduced, a majority of patients did not 
experience improved
 
hemodynamics or clinical status in the long term. One of the major 
limitations of this technique was the focus
 
on its potentially beneficial effects on wall 
stress to the
 
exclusion of considering its effects on overall pump function.
 
Specifically, 
the effects of myocardial resection on diastolic
 
ventricular properties were under-
appreciated. When expressed
 
in terms of end-systolic and end-diastolic pressure-volume 
relationships
 
(ESPVR and EDPVR, respectively), theory predicted and clinical
 
research 
later showed that despite the potentially beneficial
 
effects on systolic properties of 
shifting the ESPVR leftward
 
(increased chamber contractility), the Batista procedure was
 
also associated with counteracting effects on diastole.                                                                                                                                                             
 
The concept of using a permanently implantable passive, non-contracting wrap around 
the heart to prevent its further deterioration is not new. Suggestions have been published 
in the literature. Kass et al.[33] questioned whether an "artificial elastic sock" could be 
used in lieu of skeletal muscle. They speculated that in dynamic cardiomyoplasty, the 
latissimus dorsi wrap provides some of its benefit by acting as an elastic constraint 
around the epicardial surface. They further suggest that the passive skeletal muscle wrap 
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stiffens gradually with stretch, unlike pericardium, which is highly compliant at low 
levels of stretch but becomes very stiff when expanded beyond resting dimensions. In 
the article, the importance of gradually increasing stiffness over the entire range of 
cardiac operating dimensions is emphasized. Despite the conceptual discussion, 
however, there is no mention of how a cardiac wrap that is both elastic over the entire 
range of cardiac dimensions and gradually stiffens with stretch can be designed or built.  
                           
 Despite the prevailing sentiment that stimulated latissimus dorsi wraps should be more 
beneficial than non-stimulated wraps, the manner in which dynamic cardiomyoplasty has 
been executed clinically has limited its clinical success and clinical acceptance. The 
underlying mechanisms of dynamic cardiomyoplasty have been the focus of substantial 
investigation. Preservation of the latissimus dorsi as a power source has also been an 
issue. Because of muscle atrophy and fibrosis, the amount of squeezing power that is 
available has not been sustainable. Accordingly, there is still a need for a cardiac support 
device which does not foreshorten in the direction perpendicular to the primary direction 
of ventricular expansion, and that reduces wall stress by maintaining compressive 
contact over a significant portion of the cardiac cycle. Additionally, there is a need for a 
device that aids in preventing, in addition to treating, heart failure after acute myocardial 
infarction through attenuation of the remodeling process.  
 
Thus fundamental drawbacks of present approaches are either clinical complexity of the 
procedures or lack of efficacy because of ineffective modulation of diastolic properties. 
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The present device developed in this dissertation is an effort to mitigate these issues in a 
novel passive support device which can fully modulate the diastolic mechanics with an 
adjustable component to enable progressive therapeutic benefits with decreased 
ventricular dimensions.              
  
 
Present cardiac support devices & challenges 
Current treatment options to minimize ventricular remodeling are suboptimal. For 
example, medications such as beta-blockers and angiotensin-converting enzyme (ACE)-
inhibitors are often prescribed to attenuate cardiac remodeling and improve survival after 
myocardial infarction. However, despite a risk reduction of 15%-40%, most patients 
continue their progression to congestive heart failure, albeit at a slower rate. 
Furthermore, increasing dosages of these medications are generally associated with 
increased side-effects.  
                
Present device treatment (undergoing clinical trials) options involve surgical placement 
of a passive restraint around the heart after in patients after an acute myocardial 
infarction or end stage congestive heart failure to alleviate wall stress and thereby 
prevent subsequent cardiac remodeling Examples of devices currently in development 
include the CorCap™ cardiac support device (Acorn Cardiovascular, St. Paul, Minn.), 
the Myosplint™ device (Myocor, Inc., Maple Grove, Minn.), and the Heartnet cardiac 
support device (Paracor Medical, Inc., Sunnyvale, Calif.). 
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Fundamental problem with the inelastic nature of fabric wraps, or knits, is that normal, 
healthy changes in the dimensions of the heart are not accommodated. In addition to 
chronic pathologic changes in ventricular diameter that can occur, such as those that 
accompany remodeling, normal physiological changes also occur. The devices like 
Corcap & HeartNet (presently awaiting FDA approval) do not have the capability to be 
adjusted post-implantation. These devices have a fixed size when implanted, though the 
devices are sized smaller than the end diastolic diameter but lack of adjustability chances 
of the device losing the wrap effect is highly probable.  Thus with reverse remodeling 
the girdling effect of the device gets diminished over a period of time leading to 
reduction of the device.  
                         
One of the key aspects of devices being accepted into clinical practice is ease of surgical 
implantation and future ease of surgical intervention. All the devices presently being 
developed need to be sutured at the valve plane or needs to be attached to the 
myocardium in some way. This not only increases the time and complexity of  
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implantation but also increases the chances fibrosis over a period of time. Attachment of 
present devices to the myocardium is based on its ability to fibrose and secure itself to 
the tissue. Thus, any future surgical procedures performed to the heart can be difficult 
due to the development of fibrous tissue adhesions around the device and structures 
surrounding the heart.  
                         
The cardiac support devices under development have shown evidence in both preclinical 
and human studies that it can play an important role in both end stage heart failure and 
acute myocardial infarction by impacting the cardiac remodeling pathway. The cardiac 
support device prototyped in this dissertation is targeted towards treating end stage 
congestive heart failure. The device is also expected to prove effective in preventing 
onset of ventricular remodeling after acute myocardial infarction. This device has been 
designed to introduce fundamental innovations by introducing adjustability and other 
clinically advantageous features like intrinsic attachment negating the need to suture the 
device to heart, non-blood contacting and non- fibrotic bilayered design. This device 
would be also applicable to other structural heart diseases like idiopathic dilated 
cardiomyopathy, hypertrophic cardiomyopathy and viral cardiomyopathy.  
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Prototyping of the Cardiac Support Device                 
The cardiac support device being prototyped here is an adjustable device designed to 
enable the gradual reduction of end diastolic volume as a means to rehabilitate the heart 
muscle of patients with end-stage heart failure. The device and deployment system are 
designed for less invasive implantation through a 1-2‖ sub-xiphoid incision in sheep 
(mini left thoracotomy in humans). The device is non-blood contacting, resides in the 
pericardial space and provides support through epicardial compression. Cardiac support 
capabilities are designed to be progressively actuated over a period of months. A novel 
device has been built and multiple prototypes have been tested which has provided the 
proof of concept of the adjustable support feature of limiting the end diastolic dimension 
of the heart and shift the EDPVR demonstrating the efficacy of the design in an acute 
ovine model. To modulate the stress pattern and resultant diastolic mechanics, a 
necessary design constraint is that the diastolic and systolic configurations have normal 
cardiac curvatures. To meet these design constraints, a soft-shelled device consisting of 
inflatable, longitudinally oriented chambers that when deflated are collapsible has been 
prototyped (Figures 2 and 3). In addition, the deflated chambers are shaped and adjoined 
to form a structure that allows typical diastolic configurations. When pressurized the 
chambers push on the exterior of the heart in such a way as to induce a systolic 
configuration with normal curvatures. The side of the chambers that are on the outer 
boundary form a shape that is similar to the end diastolic shape of the heart. The inner 
sides have folds and crenulations such that when inflated the chambers mostly expand 
inward. 
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Figure 2. Schematic of cross-section of the device when deflated (left) and pressurized (right) 
without a heart inside. 
 
 
 
 
 
 
  
 
Figure 3. Schematic of long-section of the device when deflated (left) and pressurized (right) 
without a heart inside. 
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The fully pressurized shape without the heart inside is helpful for illustrating our design, 
yet the shape will be significantly different when the device surrounds a heart which 
contains blood under pressure (Figures 4 and 5). With a heart inside the pressure in the 
lumen of the device is higher than the pressure in the inflatable chambers. Since the 
chambers cannot fully expand, the inner film of the chambers is not taut. Rather than 
being supported by tension in the film, pressure on the lumen side of the longitudinal 
chambers is supported by contact forces on the epicardial surface. Without tension on 
the inner film, the attachment points are not drawn inward. Instead, the shape of the 
outer sides of the chambers becomes circular to support the pressure within the chambers 
(right side of Figure 4). 
 
Because the inflatable chambers taper (as they go from base to apex) in a manner that 
resembles natural cardiac curvature the apex of the heart will have a physiological 
curvature. Moreover, because the device is semi-rigid when pressurized, the curved 
shape of the apical end will act to prevent the heart from being expelled from the device. 
Basically, for the heart to leave the device apical shape would have to pucker or a 
vacuum would need to form in the apical end of the device—both are unlikely. 
Consequently, the device, shown in Figure 6, is implanted with minimal fixation to the 
heart. 
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Figure 4. Schematic of cross-section of the device when deflated (left) and pressurized (right) 
with a heart inside. 
 
 
 
 
 
 
 
Figure 5. Schematic of long-section of the device when deflated (left) and pressurized (right) 
with a heart inside. 
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Additionally, a biocompatible lubricant, anti-clotting agent, anti-fibrosis, or antibiotic 
agent could be injected into the space between the heart and device. So that the device 
could be removed easily after weaning, the device should be covered with an anti-
fibrotic coating or film that retards fibrous adhesions.  
 
 
 
Figure 6. Schematic of alpha prototype after it is completed. 
 
 
 
 
In summary, the major features of the design are: 
1) When uniflated the device as shown in Figure 6 has a very low structural rigidity 
such that it can be inserted and implanted through a small, sub-xiphoid incision 
(Figure 7). Similarly, explantation will be minimally invasive and done through 
an enlargement/combination of driveline tracks. 
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Figure 7. Implantation of proposed device. 
 
 
 
 
2) In case of device failure, the soft shelled nature of the device is less likely to 
impede the function of the heart. 
3) When inflated with a heart inside the device, our design takes on a systolic 
configuration with normal cardiac curvatures. The induction of this systolic 
shape intrinsically draws the heart into the device. 
4) Because the heart is intrinsically drawn into the device, there is minimal sewing 
or similar attachment to the ventricles or valve plane. Hence, valve plane 
geometry and thus valve function will be unaltered and implantation will be 
quick and performed without cardiopulmonary bypass. 
5) The amount of adjustability and hence support can be graded and thus a heart can 
gradually remodel of a period of time.  
 
Key design parameters of the device 
Table 3 below delineates the design constraints laid out for the cardiac support device. 
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Table 3 Key design parameters 
 
Key Factors 
Proposed 
Target 
Requirement 
for Success 
Present 
Practice 
Associated 
Tech Barrier 
                         
Innovative 
Solution 
 
 
Collapsibility 40 mm 40 mm 100 mm 
 
Designing and 
prototyping 
the device 
components to 
both function 
and fold 
 
Multiple 
inflatable 
chamber 
design permits 
collapse 
Status: 
Achieved 
Morphing 
Capability 
Tube to 
Fluted to 
Cup 
Shape 
Tube to 
Fluted to Cup 
Shape 
No 
Morphing 
Designing and 
prototyping 
device support 
structure to 
change shape 
accordingly 
 
 
Wire frame 
with multiple 
modes of 
storing energy 
to induce 
shape change. 
Status: 
Achieved 
 
Intrinsic 
Attachment 
No sewing 
needed 
Minimal 
sewing 
Suction 
cup 
or 
extensive 
sewing 
attachment 
Pushing on the 
heart surface 
without 
dislodging the 
heart are 
opposing 
actions 
 
Use pneumatic 
pressure 
applied to 
simultaneously 
stabilize the 
cup-like apical 
Curvature. 
Status: 
Achieved 
 
 
Failsafe 
Mechanism 
Floppy 
structure 
when 
deflated 
Floppy 
structure 
when deflated 
Non 
existent 
in 
previous 
devices 
Encircling the 
heart with a 
device to act 
on the heart 
but also not act 
are opposing 
 
Use of 
inflatable, soft 
Chambers 
makes the 
device floppy 
when deflated. 
Status: 
Achieved 
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Table 3 continued 
Key Factors 
Proposed 
Target 
Requirement 
for Success 
Present 
Practice 
Associated 
Tech Barrier 
                         
Innovative 
Solution 
 
 
Passive ED 
Adjustment 
33% 
adjustment 
of 
inner 
diameter 
10% 
adjustment of 
inner 
diameter 
0% 
adjustment 
after 
implant 
 
As the heart 
changes shape 
the device 
must change 
shape to apply 
tractions 
 
Use of 
inflatable 
chambers to 
adjust shape 
pneumatically 
Status: 
Achieved 
RV Inflow 
Adjustment 
50 mL 
obstacle in 
RV inflow 
tract 
Not known 
Not 
evident 
in prior art 
 
Left-Right 
flow is 
automatically 
adjusted by the 
systemic and 
pulmonary 
circulatory 
beds via 
unknown 
mechanisms 
 
 
By inserting an 
inflatable 
obstacle over 
the inflow 
tract, RV 
inflow can be 
reduced in a 
graded 
manner. 
Status: 
Achieved 
Diastolic 
Recovery 
15-20% 
reduction 
15-20% 
reduction 
Spurious 
recovery 
 
Development, 
growth,  
Remodeling 
processes in 
Heart 
unknown 
Mechanical 
stimuli as 
proposed are 
most likely to 
be effective 
Status: Future 
chronic  
studies needed, 
acute study 
completed 
Systolic 
Recovery 
55% 
Ejection 
Fraction 
55% Ejection 
Fraction 
Spurious 
recovery 
 
Development, 
growth,  
Remodeling 
processes in 
Heart 
unknown 
Mechanical 
stimuli as 
proposed are 
most likely to 
be effective 
Status: Future 
chronic studies 
needed, acute 
study 
completed 
41 
 
Prototype Design 
As mentioned in the study goals there were two devices fabricated which were used in 
two different studies. One of them involved sternotomy (open chest) and other study 
involved minimally invasive implantation through a inch long sub-xiphoid incision.  
 
a. Study One: Prototype for the study consisting of implantation through sternotomy: 
The prototype device implanted in this acute ovine studies had six identical 
chambers composed of a nitrile, airtight bladder surrounded by a nylon mesh to 
constrain bladder expansion and to attach adjacent bladders together via 1/8‖ width 
stitches of braided nylon thread. Each chamber had an identical helical orientation, 
but shifted 60 degrees so to form a complete circumference and form a cup-shaped 
structure. Polyurethane tubing (0.25‖ d) was employed as the conduit for fluid 
transport to and from the bladders. The chambers were also attached to a nitinol 
scaffold which provided structural stability. In this study airs was used in filling the 
passive chambers and verify the adjustable nature of the device. 
 
b. Study Two: Prototype for the study consisting of minimally invasive device 
implantation through a sub-xiphoid incision: The dimensions of the device were 
similar to previous device but the material used is nylon for this study. Figure 8 is a 
schematic of the nitinol frame of the device without the adjustable port.  
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Figure 8. Prototype of the cardiac support device with nitinol elements which provides the 
structural rigidity to the device. 
 
The Figures 9 & 10 depict the polymeric multi-chambered support device deployed 
about an excised ovine heart (Figure 9) and fluoroscopic image of a fully deployed 
device with the chambers filled with contrast-saline solution for imaging (Figure 10). 
This prototype forms the foundation of a novel device which was studied in vivo to test 
the various device parameters and also functionality as whether it can modulate the 
diastolic properties. 
 
43 
 
 
Figure 9. A prototype of the polymeric multi-chambered support device deployed about an 
excised ovine heart that is preserved and wrapped in thin latex for handling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 10. Fluoroscopic image of a fully deployed device.  The passive chambers are 
filled with contrast-saline solution for imaging.  
 
 
 
Contrast filled 
Passive Chambers 
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The overall device in this chapter being studied here is similar in design to that of the 
thesis project of Michael Moreno; the primary distinction between the Moreno thesis 
project and the project herein is that Moreno device was focused on combining an active 
assist device with an passive support whereas the project herein was devoted to studying 
a standalone adjustable support device. For the acute implant studies Dr. Criscione chose 
to combine the assist and support actions into a single device to maximize the use of 
financial and animal resources. The data runs related to device operation with support 
aspect of the device being functional only is being presented in this project here. 
 
 
 
In vivo Studies: Animal Model and Experimental Set-Up 
Surgical Procedure: The care and use of the sheep in this acute implant study and 
terminal procedure was conducted at the Texas A&M University College of Veterinary 
Medicine in accordance with an active animal use protocol approved by the Institutional 
Animal Care and Use Committee of the Texas A&M University System. The adult 
sheep, which weighed approximately 70 kg, was premedicated with an anti-anxiety drug 
(Xylazine 0.075 mg/lb) and an anticholinergic (Glycopyrrolate 0.01 mg/kg).  Both drugs 
were given intramuscularly.  After sedation a 16 g catheter was placed in the left jugular 
vein and anesthesia was induced with Ketamine (4.4 mg/kg) and Diazepam (0.11 mg/g) 
mixed together and given intravenously (IV) to effect. After induction, the animal was 
placed sternal and an endotracheal tube of appropriate size was placed and the animal 
connected to the anesthesia machine. Anesthesia was maintained with isoflurane gas at a 
concentration of 2-4% throughout the procedure.  The animal was clipped and prepped 
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for sternotomy, 16g jugular catheter was replaced with an 8 French quad-lumen catheter 
to allow multiple IV access, and an orogastric tube was placed to prevent bloating.  An 
arterial catheter was placed in the left dorsal pedal artery to allow for direct blood 
pressure monitoring.  The animal was placed in dorsal recumbuncy for the remainder of 
the study.  Supporative IV fluids and mechanical ventilation were started.  Using a 
Power Lab physiological monitoring unit; heart rate, blood pressure, central venous 
pressure, oxygen saturation, ECG, and respirations were monitored throughout the 
procedure.  A lidocaine CRI was started to prevent arrhythmias and Buprenorphine 
(0.02-0.05 mg/kg) was administered for pain. A Millar PV Catheter was placed through 
a left carotid artery cut-down and positioned by use of fluoroscopy. A sternotomy was 
performed and the device was placed over the heart apex. The xiphoid process was 
removed, and the device drivelines and chest tube were routed caudal to the sternum. 
The sternum was closed with wire and the fascia was closed tightly with suture to create 
a pneumatic seal. Free air in the chest was evacuated.  
  
Using the PVAN software (Millar Instruments Inc., Houston TX), cardiac function was 
evaluated. Pressure-volume (PV) relationships were determined for three cardiac states: 
normal, vena cava occlusion, and esmolol induced failure. Measures of heart rate (HR), 
maximum pressure (Pmax), minimum pressure (Pmin), maximum volume (Vmax), 
minimum volume (Vmin), end-diastolic pressure (Ped), end-diastolic volume (Ved), 
end- systolic pressure (Pes), end-systolic volume (Ves), stroke volume (SV), ejection 
fraction (EF), cardiac output (CO), and stroke work (SW) were obtained. The 
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aforementioned values were calculated for each PV loop acquired. A minimum of six 
loops were acquired for each case. Mean values and standard deviations were calculated 
for each case using the PVAN software package. These values were then used to 
determine statistical significance via a t-test with p=0.05. To assess diastolic mechanics, 
the end-diastolic pressure volume relationship (EDPVR) was measured by use of a 
balloon catheter inflated in the caudal cava to reduce the pre-load on the heart. To model 
acute heart failure, an overdose of esmolol was administered. This included four boluses 
of 33mg each for a volumetric sub-total of 13.2ml (0.5-1.0mg/kg), and a constant rate of 
infusion (CRI) of 0.5-2.0 mg/kg/min for a volumetric sub-total of 15.18ml, and thus a 
total volume of 28.38ml esmolol administered.   
 
Results: In vivo Proof-of-Concept of Adjustable Support Device 
 
 
1. Successful implantation of the adjustable cardiac support device: After multiple 
design iterations and testing of prototypes on a bench-top model of the ovine heart, 
implantation was accomplished as shown in the fluoroscopic image in Figure 11. 
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Figure 11. Device placed on the ovine heart and chambers filled with contrast agent. 
 
2. Intrinsic pneumatic attachment: The device takes on a cup like shape (i.e., 
structurally supported cavity) when it is pressurized, and this naturally draws the 
heart into the device—such that suturing to the heart is not required. Once air in the 
mediastinum is removed, the heart and device are pneumatically locked in a co-axial 
configuration. This feature was also verified by fluoroscopic imaging.  
 
3. Study One: EDPVR Passive Constraint/Support with air to adjust the passive 
chambers with device implanted through median sternotomy: Changes in the filling 
pressure of the left ventricle, known as preload, move the end-diastolic point, the 
lower right-hand corner of the PV loop. These points can be approximated in a linear 
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fashion and are collectively known as the end-diastolic pressure-volume relationship 
(EDPVR), which represents the passive filling mechanics of the left ventricle. One of 
the objectives of the study was to show how the device‘s passive constraint/support 
component could alter the EDPVR in a positive manner. The preload was altered by 
occluding the vena cava with a balloon. The vena cava occlusion was first done with 
a passive constraint of 0mmHg to develop a baseline EDPVR. The PV relationship 
was recorded for approximately twenty cardiac cycles after the occlusion as shown 
in Figure 12. After the heart recovered, the vena cava was occluded again but this 
time the cardiac support device applied a passive constraint pressure of 7.5mmHg. 
Again, the PV relationship was recorded for approximately twenty cardiac cycles. 
The end-diastolic points for each PV loop are plotted in Figure 13. The plots of the 
EDPVR for the 0mmHg versus the 7.5mmHg show that the EDPVR shifted upward 
with the 7.5mmHg passive constraint. This upward shift in the EDPVR indicates a 
decrease in the size of the left ventricle relative to pressure, i.e. the ventricle 
maintains the same filling pressure at a smaller volume. Therefore, the passive 
constraint is capable of manipulating the end-diastolic volume.  
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Figure 12. (Top) PV loops of left ventricle during vena cava occlusion with a passive constraint 
of 0mmHg. (Bottom) PV loops of left ventricle during vena cava occlusion with a passive 
constraint of 7.5mmHg. 
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Figure 13. Plot of end-diastolic pressure-volume relationship for vena cava occlusion with a 
passive constraint of 0mmHg versus 7.5mmHg. 
 
 
 
 
4. Study two: EDPVR Passive Constraint/Support with saline to adjust the passive 
chambers with device implanted in a minimally invasive manner through sub-
xiphoid incision:  The vena cava occlusion was first done with the passive support 
chambers filled with 0mL of saline to establish a baseline EDPVR as shown in 
Figure 14 (Note: In the previous study air was used in the passive chamber). After 
the heart recovered, the vena cava was occluded again but this time the passive 
component of the CSD was filled with 40 mL of saline. The end-diastolic points for 
each PV loop are plotted in Figure 15. The plots of the EDPVR for the 0mL versus 
the 40mL show that the EDPVR shifted leftward. This shift in the EDPVR indicates 
a decrease in the size of the left ventricle relative to filling pressure, i.e. the ventricle 
maintains the same filling pressure at a smaller volume.  
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Figure 14.  (Left) PV loops of the left ventricle during vena cava occlusion in the absence of 
passive support, i.e. cardiac support of 0.0 ml. (Right) PV loops of the left ventricle during vena 
cava occlusion with 40mL of passive support. 
 
 
 
 
 
Figure 15. Plots of the EDPVR for both the 0mL of support and 40mL of support. 
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Bench-Top Proof- of- Concept of Adjustable Support Device 
 
The bench-top study was conducted to obtain EDPVR‘s from a model heart and with the 
passive component of the proposed device in action to test the adjustable nature of the 
device and its impact on EDPVR; thereby allowing comparisons to be drawn between 
EDPVR‘s between acute ovine studies and bench-top studies. The plots of the EDPVR 
for the 0mL versus the 40mL was obtained with the goal being to study whether there is 
a decrease in the size of the left ventricle relative to filling pressure, i.e. the ventricle 
maintains the same filling pressure at a smaller volume.  
 
The project consisted of two phases.  In the first, a model was created to mimic the 
EDPVR of a human heart.  A model of the normal heart as shown in Figure 16, was 
chosen because the mechanics and response of the normal heart are better known and 
easier to model than the failing heart‘s complicating structural and mechanical 
alterations, and a model of the normal heart is sufficient to meet the goal of 
demonstrating the device‘s ability to effect modulation of end diastolic volume and 
impact on the pressure volume relationship.  This model was used to set baseline values 
for later comparison to the results when the device was tested.  Once a satisfactory 
model was built, the device (Figures 17 and 18) was tested using the experimental setup 
described in the remainder of the section. A model of the heart was constructed that 
simulated the EDVPR (end-diastolic pressure-volume relationship) of a normal human 
heart.  The model was formed by creating a bladder approximately the size of both 
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normal human ventricles.  The bladder was rigid upon full inflation, thus approximating 
the shape of the normal human heart.  
  
The experimental setup is conceptually simple: pressure or volume was incremented, 
and therefore, known, while the corresponding change in the other variable (volume or 
pressure, respectively) was measured.  The results were then plotted to create an 
EDPVR.  At the outset of the project, volume was used as the independent variable, and 
incrementally increased while the corresponding change in pressure was measured using 
a manometer.  This approach concentrated the readings in the low pressure region of the 
EDPVR, as incremental changes in volume led to major pressure changes as volume 
increased.  Additionally, because a small volume change could create a major change in 
pressure at high volumes, it was difficult to create stable, easily repeatable relationships.  
To avoid these problems, pressure was made the independent variable.  Pressure was 
incrementally changed by varying the difference in height between the model and a 
water reservoir.  The volume change in the water reservoir corresponding to each 
pressure change was measured, and the results plotted to create an EDPVR.  The 
experiment was designed to increment the model‘s volume, and measure the 
corresponding change in pressure.  The results were then plotted to create an EDPVR. 
Figure 19 illustrates this setup.  
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Figure 16. Heart model (top) Schematic design of the heart model in the experimental setup with 
uninflated support device placed on it; (bottom) Prototype of the model which is used to measure 
EDPVR of a normal heart. 
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Figure 17. Cardiac support device (top) Schematic design of the inflated cardiac support device 
placed on the heart model in the experimental setup; (bottom) Prototype of the cardiac support 
device on the heart model which is used measure EDPVR.  
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Figure 18. Prototype of the cardiac support device that was placed on the heart model in the 
experimental setup.  
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Figure 19.  Close-up illustration of heart model, pericardial sac model, and cutaway device 
inflated passive support chamber. 
 
 
 
Pressure readings were taken at 5 cmH2O intervals.  The heart has a normal left 
ventricular end-diastolic pressure of approximately 15 mmH, or 20 cmH2O; thus, 5cm 
intervals were determined to be sufficient to allow an accurate EDPVR to be obtained. In 
order to obtain an accurate comparison and eliminate as much error as possible, new 
baseline values of the heart model alone were taken at the beginning of every trial.  Once 
a baseline EDPVR was obtained, the passive support device was employed.  The set of 
EDPVRs was obtained for the model heart and device along with the model at two 
volumes with gradual adjustment. 
Device in 
Vacuum out 
Fluid in 
passive 
chambers 
Pericardial 
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Support 
chamber 
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It is important to note that the device is not physically secured to the nitinol frame 
support structure; therefore, the diastolic support component relies on the presence of a 
vacuum to cause the ventricle walls to adhere to the device and follow it outward when it 
recoils as the heart enters diastole.  In the body, the pericardial sac that surrounds the 
heart provides a vacuum.  In this experimental setup, the pericardial sac was modeled by 
a vacuum drawn, as shown in Figure 20, in a sac placed around the heart model and 
device. 
 
 
 
 
 
Figure 20. Device set-up to model a pseudo-pericardial sac. 
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Results: Bench-Top Study of Adjustable Support Device 
End-diastolic pressure-volume relationship (EDPVR), which represents the passive 
filling mechanics of the left ventricle, was obtained in this bench-top study using a mock 
heart model. One of the objectives of the study was to show how the device‘s adjustable 
passive constraint/support component could alter the EDPVR in a positive manner and 
have comparable outcomes with the ovine studies. In the experiment three data runs 
were done, one with heart model only, second passive device with 0ml of water and third 
passive device with 40 ml of water. Figure 21, shows the baseline EDPVR of the heart 
model on the right. The device then placed on the model with passive support chambers 
unfilled (0mL of water) and a EDPVR was obtained.  In the next data run the passive 
component was filled with 40 mL of water and EDPVR data taken. The EDPVR‘s are 
plotted in Figure 21. The plots of the EDPVR for the baseline heart model vs 0mL 
versus the 40mL show that the EDPVR shifted leftward with gradual decline in end 
diastolic volume. This shift in the EDPVR indicates a decrease in the size of the left 
ventricle relative to filling pressure, i.e. the ventricle maintains the same filling pressure 
at a smaller volume. Therefore, the passive constraint is capable of manipulating the 
end-diastolic volume.  
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Figure 21: Bench-top verification of adjustable passive device with a fillable, pseudo-heart 
mimicking the baseline EDPVR. With the device placed on the pseudo-heart inside a sac with air 
evacuated (like the mediastinum) leftward shift of EDPVR and adjustability is evident. 
 
 
 
Discussion 
 
Over the last decade multiple studies have demonstrated the utility of cardiac support 
devices which function as passive ventricular
 
restraint to mitigate the deleterious 
changes triggered by ventricular remodeling as a consequence of heart failure [15,34]. 
Presently awaiting FDA pre-market approval are the most studied ventricular restraint 
devices,
 
such as the Corcap [35-48], Myosplint [49-52], Coapsys [53-57], and the 
Heartnet [58-62] do not have any means to adjust the therapy once implanted as the heart 
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is
 
wrapped in prosthetic material to reduce ventricular dilatation over a period of time. 
The cardiothoracic surgeons implant the device ‗snugly‘ on the epicardial surface thus 
providing no control over the modulation of the end diastolic volume, so once the device 
is placed at the
 
initial procedure, the level of restraint is constant and unchanging,
 
even 
as the heart undergoes reverse remodeling.  The inability of current restraint devices to 
adjust
 
restraint level and develop a therapeutic regimen to direct the heart towards a 
progressive reverse remodeling is a major drawback of the present devices.  
  
The motivation of this device design was triggered by the premise that mechanical 
stimuli are critical factors for guiding the growth, remodeling, and maintenance of 
cardiac functions in a normal state. Hence a device therapy to intervene in a pathological 
state would need a fundamental design innovation which creates a normal physiological 
environment. Under normal conditions contractile proteins are in a constant state of flux 
being added at rates about equal to half of the heart muscle mass per week. The 
myocardium is continuously reconstituting itself by processes that are guided by 
physiologic demand and the mechanical environment in which the heart must function. 
Thus it is hypothesized that with passive constraint and systematic reduction of an 
enlarging diseased heart, natural growth and remodeling processes can be directed such 
that they are restorative and thereby therapeutic intervention is rehabilitative. The non-
adjustable passive CSDs are designed to resist chronic dilation of end-diastolic volume, 
as well as reduce ventricular wall stress and myocardial stretch. Thus over long terms 
these devices can induce reverse remodeling toward normal size and function. But one 
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of the major factors which limit the efficacy of the present CSDs is the lack of device 
adjustability with progressive reverse remodeling. With a change in ventricular 
dimensions caused by reverse remodeling there is a mismatch between relative geometry 
of the device as compared to the ventricular dimensions. Consequently, in order to 
achieve full reverse remodeling an adjustable device is desirable wherein the mechanical 
conditions required to sustain restorative remodeling can be maintained until normal 
size, shape, and function are achieved by natural growth and remodeling processes.  
 
The adjustable cardiac support device prototyped and tested in this dissertation 
introduces an innovation in the class of passive support devices which for the first time 
introduces a minimally invasive support device which can fully modulate the diastolic 
mechanics. In the in vivo studies,
 
we showed that adjustable restraint level shifts the end 
diastolic pressure volume relationship leftward indicating the device improves the 
passive diastolic properties revering the ventricular dilatation. We postulate that periodic 
adjustment
 
of device through the subcutaneous port would be needed post-implantation 
to maximize
 
therapeutic efficacy as the ventricle reverse remodels.
 
 
 
In our acute study we have adjusted the support level based on PV loop data using both 
air and saline to modulate the end diastolic volume.  The goal of this study is to 
demonstrate the feasibility of
 
a prototype cardiac support device which can modulate the 
end diastolic volume real time in an acute ovine model. In a clinical set-up we expect 
that the post-implantation
 
adjustment of the device would be performed using real-time 
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echocardiographic data. Present devices undergoing FDA approval do not provide an 
option of post implantation adjustment. In our present study the device adjustment to 
modulate the end diastolic volume (EDV) in an ovine model was
 
performed 
percutaneously
 
after device
 
implantation. We expect in a clinical set up all these 
activities would be performed outside
 
of the operating room in a minimally invasive 
fashion utilizing
 
physiologic parameters to guide therapy application.   
 
The two in vivo studies we did were limited to evaluate the proof of concept of 
adjustability using two possible mediums. It is expected in a clinical set up a saline 
would be a more viable option to adjust the device. The main goal of performing this 
study is to demonstrate that an adjustable device can be implanted safely in a minimally 
invasive surgical procedure and the device can be adjusted postoperatively without any 
adverse physiological effect. With future ovine chronic heart failure model studies more 
questions regarding the protocol of the therapy would be answered like duration of 
device adjustment post implantation, quantitative assessment of long-term reverse 
remodeling and comparison of
 
overall efficacy with present heart failure solutions.
 
 
 
Conclusion 
In conclusion we have successfully prototyped and tested on a bench-top and in vivo a 
passive support device with adjustable passive chambers to modulate end diastolic 
volume in real time.  Two different device designs have been tested with one being 
implanted through sternotomy and other one implanted in a minimally invasive manner 
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through a one inch sub-xiphoid incision. The device has been tested with both saline and 
air and implanted in an acute ovine model where the implantability, attachment and 
ability to modulate end diastolic pressure volume relationship was successfully tested to 
adjust the device size. Other clinically advantageous features like intrinsic pneumatic 
attachment negating the need to suture the device to heart, non-blood contacting and 
non- fibrotic bilayered design have also been incorporated in the design. Though this 
device is clinically targeted towards patients with systolic dysfunction caused by an 
infarct but it would also be applicable to other structural heart diseases like idiopathic 
dilated cardiomyopathy, hypertrophic cardiomyopathy and viral cardiomyopathy. With 
the design features incorporated in the device a wide range of mechanical effects can be 
examined in chronic heart failure models so that a diseased hypertrophied heart can be 
gradually returned to normal size with restoration of function. The underlying goal of 
this device therapy would be to ultimately create the conditions under which natural 
growth and remodeling processes are guided in a physiologically appropriate manner to 
introduce the natural mechanical feedback loops.  
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CHAPTER III 
 
DEVELOPMENT OF A NOVEL DIASTOLIC RECOIL DEVICE 
TO IMPROVE VENTRICULAR FILLING 
 
   
Introduction 
Heart failure which is manifested as left ventricle's inability to generate sufficient 
cardiac output, is commonly associated abnormalities in systolic function (emptying of 
left ventricular chamber), but its symptoms may also arise as a result of diastolic (filling 
of left ventricular chamber) dysfunction. Diastolic dysfunction might be present in both 
normal and abnormal systolic performance. In the event of diastolic dysfunction there 
are moderate to severe changes in ventricular diastolic properties with a deleterious 
effect on ventricular diastolic pressures and ventricular filling. An integral part of normal 
diastolic filling is the contribution of the left ventricular (LV) elastic recoil forces to the 
LV filling. Elastic recoil forces are generated within healthy myocardium during systolic 
shortening. The magnitudes of elastic recoil forces are inversely proportional to the 
volume of the LV, i.e., they increase as the LV volume decreases. Their contribution is 
important in early diastole because they allow rapid and enhanced early filling by 
assisting the expansion of the left ventricle. In a case of ventricular enlargement and/or 
the decrease of myocardial function due to hypertrophy the left ventricular elastic recoil 
forces may be diminished or nonexistent, therefore ceasing to assist early ventricular 
filling and leading to an increase of the ventricular filling pressure. In this chapter the 
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problem of ventricular filling is being addressed with prototyping of devices which can 
increase using diastolic filing by increasing the recoil effect. 
 
Study Goals 
With an understanding of the present state of the art in diastolic recoil devices and 
prominent role of torsional mechanics and understanding that early diastolic filling is 
directly related to the active process of LV relaxation leading to a ‗suction‘ effect' , a 
novel device design has been conceptualized to mitigate the present challenges of the 
diastolic recoil devices. To advance the feasibility of the concept and the device design 
our goal is:  
 
Prototyping of a recoil device to augment ventricular suction during diastole:  
Modification of the adjustable support device design to incorporate design features to 
integrate recoil effect in a single device. The goal of this device is to augment the 
torsional untwisting during diastole and increase the diastolic filling. Successful 
achievement of these milestones is central to proceed towards chronic experiments to 
assess heart remodeling—i.e., the next phase of studies.  
 
 
Background 
                      
The term diastolic heart failure (DHF) generally refers to the clinical syndrome of heart 
failure associated with a preserved left ventricular EF, in the absence of major valvular 
disease [63]. Forty percent of incident CHF cases and 50–60% of prevalent CHF cases 
67 
 
occur in the setting of preserved systolic function [64]. Mortality rate among patients 
with DHF is considered lower than in systolic heart failure [65]. Some challenge this 
notion, showing that the natural history of patients with DHF may not be different from 
that of patients with systolic heart failure [64, 66]. The morbidity and rate of 
hospitalization are similar to those of patients with systolic heart failure [63, 66]. Due to 
its higher prevalence in the elderly population, the incidence of DHF is expected to rise 
with the increased aging of the western world population.  
 
Of the 5.7 million people in the US and 25 million people worldwide who suffer from 
heart failure, between 30-55% of these patients suffer from diastolic heart failure (DHF) 
and are without effective treatment. The term diastolic dysfunction indicates abnormal 
diastolic distensibility, filling, or LV relaxation, regardless of whether the ejection 
fraction is preserved or abnormal or whether the patient is symptomatic or 
asymptomatic. The terms Diastolic heart failure (DHF) and Heart failure with normal 
ejection fraction (HFNEF) are used to describe patients with the signs and symptoms of 
heart failure, a preserved ejection fraction, and LV diastolic dysfunction [67]. Diastolic 
heart failure is most common in elderly patients and women with a history of essential 
hypertension, ventricular hypertrophy, diabetes, and cardiac ischemia [68]. As a result of 
the condition, mortality, morbidity, and healthcare costs are high [69]. Although DHF 
typically has a lower in-hospital mortality rate than systolic heart failure, hospitalization 
frequency for both conditions is comparable [70, 71]. Epidemiological studies have 
suggested that 30% to 50% of patients with active congestive heart failure (CHF) have 
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adequate LV systolic function [72-76]. Kitzman et al [76] found that 8% of patients 
older than 65 years have heart failure, 55% of whom have a preserved LV ejection 
fraction (LVEF). In addition, diastolic dysfunction has been shown to affect elderly 
women more than any other population subgroup [73, 74, 77]. Patients who have 
diastolic dysfunction are twice as likely to have diabetes mellitus [76]. Other commonly 
associated conditions include hypertension, renal dysfunction, myocardial ischemia, and 
ventricular hypertrophy [78]. Patients with DHF have a preserved ejection fraction 
despite increased LV diastolic pressure and pulmonary venous pressure. These patients 
have both increased passive stiffness and abnormal active relaxation of the left ventricle, 
which may work independently to cause abnormal diastolic physiology [79]. This effect 
has been suggested by showing that even after correction for slow relaxation, increased 
passive stiffness was found to be an important factor in LV diastolic dysfunction and 
DHF [79]. Under such conditions, the left ventricle typically cannot fill to the minimal 
volume without elevating diastolic pressures, eventually leading to pulmonary 
congestion, which in turn leads to DHF [80-82]. Ventricular relaxation, as an energy-
dependent process, may be impaired by decreased availability of adenosine triphosphate 
(ATP) and changes in calcium metabolism [80, 83]. Removal of calcium from the 
cytosol may be delayed by a decrease in the activity of sarco/endoplasmic reticulum 
calcium adenosine triphotphase (SERCA) or an increase in the level of activity of 
phospholamban, which is a SERCA-inhibitory protein [80, 84, 85 ]. Pathologic 
ventricular hypertrophy, secondary to hypertension or aortic stenosis, with impaired 
relaxation of the ventricular muscle leads to a decrease in SERCA levels. Similar 
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changes are seen in the myocardium of patients with hypertrophic or dilated 
cardiomyopathy. One animal study [86] showed that the calcium pump rate in the 
sarcoplasmic reticulum is diminished in the hearts of senescent rats compared with 
younger rats. Levels of SERCA are also known to decrease with age. Older hearts have 
degenerative changes in the myocardium and reduced β-adrenergic tone [87].  
 
Theoretical Foundation 
 In a case of ventricular enlargement and/or the decrease of myocardial function due to 
hypertrophy the left ventricular elastic recoil forces may be diminished or nonexistent, 
therefore ceasing to assist early ventricular filling and leading to an increase of the 
ventricular filling pressure. Implantation of the diastolic recoil device in the ischemic 
and enlarged ventricle may bring back the ability of the ventricle to store elastic energy 
during systole and return this energy in the form of elastic recoil forces during diastole. 
In a diastolic recoil device, this return of energy in the form of elastic recoil may 
contribute to the improvement of the diastolic function, i.e., decrease of the filling 
pressure and increase in the magnitude of the early filling in patients with ischemic 
and/or dilated cardiomyopathy. Intervention to alleviate the resultant symptoms of the 
physical changes described above may offer great benefit to patients with congestive 
heart failure or dilated cardiomyopathy. Administration of vasodilators, diuretics, 
sodium channel blockers, and inotropic agents have been used to reduce the number of 
acute events and slow the advance of disease, but cannot reverse the physical changes to 
the heart. Surgical intervention can reduce the volume of the ventricle such that cardiac 
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function is improved but carries high risk for the patient. Other less invasive modes of 
intervention offer improved function while reducing risk for the patient during and after 
the procedure. 
 
Present Diastolic Recoil Devices  
The treatment of patients with diastolic heart failure is mainly empirical. The treatment 
includes modification of the underlying risk factors for the disease (such as hypertension 
and diabetes) and administration of medications used for treating systolic heart failure. 
Presently, there are no medications or devices that can specifically improve left 
ventricular relaxation and diastolic function. There is a wide range of devices aimed to 
treat systolic heart failure, including left ventricular assist devices (LVAD) and 
biventricular pacing devices, all in clinical use. None of these devices can present a 
solution for the many DHF patients since they do not improve LV relaxation and filling. 
Diastolic heart failure therapies presently include mostly pharmaceutical products and 
there are few, if any, devices available. There are presently no approved devices for 
treatment of the DHF symptoms. However, clinical stage recoil device concept, Imcardia 
(Corassist Inc) has a potential role in the treatment of DHF patients.  
 
Imcardia (Corassist): The ImCardia™ is an elastic self-expanding device that is attached 
to the external left ventricle surface of the heart through a simple off-pump procedure. It 
applies an outward expansion force on the ventricular wall to improve diastolic dynamic 
and filling performance. In vivo Safety evaluation on healthy model demonstrated that 
71 
 
the device is safe at 6 month follow up (including: systolic performance, general clinical 
evaluation and extreme conditions tests). In vivo Efficacy evaluation on diseased animal 
model with hypertrophic left ventricles revealed diastolic properties improvement. 
Ongoing results from Clinical safety study in which the ImCardia is implanted in 
patients admitted for Aortic valve replacement due to Aortic stenosis and suffering from 
Diastolic Dysfunction showed safety profile with first patients reaching 1 year follow-
up.  
 
Left Ventricular Twist Mechanics and Suction Effect in Diastolic Filling 
 
The twisting motion of the left ventricle about its long axis results from the contraction 
of the obliquely oriented epicardial and endocardial fibers. Cardiothoracic surgeons 
intuitively check this twisting movement as a sign of healthy left ventricular (LV) 
function. Lower [88] studied LV torsion in the late seventeenth century. He described 
the twisting motion of the left ventricle as ―the wringing of a linen cloth to squeeze out 
the water.‖ Over the past 3 centuries, experimental and clinical explorations on LV twist 
have entailed the use of numerous techniques such as implanted radiopaque markers 
[89], biplane cineangiography [90], sonomicrometry [91-92], optical devices [93], 
gyroscopic sensors [94], MRI [95-97], and echocardiography [98-101]. Furthermore, the 
rapid pace of technologic advancements has resulted in the development of innovative 
techniques in which LV twist is readily computed from gray-scale cardiac ultrasound 
images obtained at the bedside. Torsion helps bring a uniform distribution of LV fiber 
stress and fiber shortening across the wall [102]. It has been demonstrated in a 
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mathematic model that normal torsion causes sarcomere shortening of 0.20 μm in the 
epicardium and 0.48 μm in the endocardium [103]. Elimination of the torsion, however, 
decreases epicardial shortening (0.10 μm) and increases endocardial shortening (0.55 
μm). Thus, disappearance of torsion would increase endocardial stress and strain and 
increase oxygen demand, thereby reducing the efficiency of LV systolic function. In the 
subendocardium, torsion causes fiber rearrangement such that subendocardial fibers are 
sheared toward the left ventricle cavity for LV wall thickening while the left ventricle 
base is pulled toward the apex, shortening the longitudinal axis of the left ventricle. 
Torsion also provides a key association between systole and diastole. Twisting and 
shearing of the subendocardial fibers deforms the matrix and results in storage of 
potential energy during systole, then abruptly releases with sudden untwisting during 
isovolumic relaxation, generating intraventricular pressure gradients for LV diastolic 
filling [91]. 
 
Prototyping of a Novel Diastolic Recoil Device 
 
The device being prototyped, shown in Figure 22, has following design requirements so 
that it can fulfill the following functions: 
 Device is capable of exerting elastic forces on the external ventricular wall in a 
tangential direction, in addition to the externally-directed radial forces. These 
tangential forces are of importance for the following two reasons:  
                   1. Allows even distribution of applied forces across the left 
ventricular wall surface;  
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                   2. Assist the diastolic movement during untwisting of the left 
ventricle in a manner more similar to its normal physiological torsional 
mechanics.  
 Anatomically and physiologically compatible 
 Biocompatible and configured for compact and long-term implantation.  
 Readily adapted to the precise topographic conformation of the heart  
 Delivered in a minimally invasive manner.              
 
 
 
Figure 22. Diastolic recoil device prototype with nitinol elements. 
 
 
The diastolic recoil device being prototyped here is designed for clinical conditions like 
diastolic dysfunction, mitral valve regurgitation or heart failure. During diastolic phase 
of cardiac cycle the myocardial relaxation occurs leading to ejection of blood to systemic 
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circulation. The active and passive properties of the myocardium, geometrical 
characteristics of the chamber and external forces play an important role in the 
modulation of diastolic mechanics.  A reduction in ventricular compliance (i.e., increase 
in stiffness of ventricular heart wall) may result in less diastolic expansion of the 
ventricle, less ventricular filling (i.e. decreased end-diastolic volume EDV) and a greater 
diastolic pressure, resulting in a change in the ventricular diastolic pressure-volume 
characteristics. In a case of ventricular enlargement and/or the decrease of myocardial 
function, the left ventricular elastic recoil forces may be diminished, therefore leading to 
increase of the ventricular filling pressure. The device designed here in is the first device 
which in a minimally invasive manner can impact all the metrics of diastolic mechanics. 
The novel diastolic recoil device developed here is an innovation over the cardiac 
support device explained in CHAPTER II and there is a fundamental difference in 
design between the two devices. Though on initial review it might seem to a simple 
change in coil pattern but the difference between the two designs provides this diastolic 
recoil device the ability to store energy during the cardiac cycle. This stored energy is 
responsible for higher ventricular filling in ventricle with pathological passive 
properties. The device described here is made of nitinol elements which elastically 
distorts during systole and recoils during diastole to augment the ventricle's natural 
recoil action. Implantation of the present design would lead to enhanced diastolic recoil 
resulting in storing compressive forces in the elastic NiTi frame of the device. The origin 
of compressive forces is a bending deformation of the resilient frame. The decrease of 
the unconstrained frame diameter to the end systolic dimensions leads to flexing 
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deformation of the elements triggering a rebounding force attempting to return the frame 
to the unconstrained diameter. These outward recoil forces are transmitted to the 
myocardium thus applying pressure against the wall of the ventricle. The diastolic recoil 
device is elastic and its configuration changes from a small diameter at end-systole to a 
larger diameter at end-diastole. The compression of the diastolic recoil device from end-
diastolic to end-systolic configuration causes additional compressive forces to be stored 
in the elastic frame of the device and is designed to be substantially equivalent at end 
systole to the elastic restoring forces that originate in the myocardium in a healthy heart. 
Thus the amounts of outward recoil forces that are transmitted to the walls of the 
ventricle during diastolic filling are enhanced and augment outward motion of the 
ventricular walls. Resultantly, stress is decreased in the myocardium, which is beneficial 
for more efficient mechanical function. As stress is a major cause of dilation, 
implantation of a device and its contribution of recoil forces back to the heart wall may 
limit remodeling in the ventricle. The Figures 23 and 24 show the design innovation 
incorporated in the cardiac support device to utilize the same design platform into a new 
recoil device which can store energy during systole and release during diastole. This 
innovation leads to improved ventricular filling along with limiting diastolic volume. 
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Figure 23. Cardiac support device: Open nitinol element design provides the device structural 
rigidity and also makes it collapsible enabling minimally invasive implantation.  
 
 
 
 
 
Figure 24. Diastolic recoil device: Refinement of cardiac support device by overlapping of the 
nitinol elements providing storage of potential energy at the time of systolic contraction. 
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This storing and release of energy by the frame occurs in synchrony with the action of 
the heart. This transfer of energy may decrease the ventricular pressure in diastole, 
increase the atrio-ventricular pressure gradient, increase filling, and thus improve 
ejection fraction. Dyskinetic or aneurystic ventricular walls result in dyssynchronous 
behavior during the cardiac cycle, leading to inefficient pumping function. The present 
device can play an important role also in removing those dyssynchronous contributions 
to heart rhythms, restoring overall synchrony in the cardiac cycle, and thus improve 
ejection fraction. The active recoil elements of the device are made of nitinol. It has the 
advantageous capability of being able to remain elastic over a great range of strain, up to 
4%, which is greater than other metals.  
 
Discussion 
 
The heart spends more than half its time in diastole (relaxing
 
and then filling to prepare 
for the next ejection). Although
 
abnormalities of diastolic function are well recognized 
and
 
common to virtually all forms of heart failure, just how they
 
affect basal and reserve 
function and their relative role in
 
clinical heart failure remain unclear. There are a 
number of
 
reasons for this. First, diastole assessment ideally requires
 
invasive 
measurements that are nontrivial to obtain, whereas
 
noninvasive surrogates often 
reported in clinical studies reflect
 
integrative properties that lack specificity. Second, 
relatively
 
few animal models recapitulate human diastolic disease, particularly
 
chamber 
stiffening, which is often normal in murine models despite
 
extensive matrix, 
myofibrillar, or signaling abnormalities.
 
Third, there are few if any targeted treatments 
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that can specifically
 
test the impact of altering diastolic function on heart failure
 
pathophysiology and outcome. Last, diastolic function has been
 
less amenable to 
reductionist approaches given the potent roles
 
that chamber geometry, loading (both 
intrinsic and extrinsic
 
to myocytes), extracellular matrix, and myocardial perfusion
 
all 
bring to bear. 
 
This rapid early diastolic untwist in normal people may be an important component of 
the phenomenon known as diastolic suction where blood is actively ‗sucked‘ into the LV 
from the LA [104].
 
It is this suction effect that is diminished in the earliest stages of 
diastolic dysfunction
 
and hence this may be reflected in decreased apical untwist before 
changes in the standard diastolic parameters. This may explain the moderate correlation 
between the traditional diastolic criteria and the untwist parameters since the former 
reflects pressure and flow differences between the atria and ventricle while the latter is 
more likely the precursor and reflects intrinsic LV myocardial mechanics [104]. It 
remains widely presumed that
 
diastolic abnormalities are important to heart failure 
pathophysiology,
 
and this is driving new research to elucidate the biochemical
 
and 
structural mechanisms that underlie it, clarify its role
 
to clinical heart failure, and 
develop targeted treatments for
 
it. Important insights are being gleaned from genetically 
engineered
 
models that facilitate molecular hypothesis testing in the intact
 
chamber.  
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Conclusion 
In this chapter we have documented the design and prototyping of a diastolic recoil 
device that can enhance filling of a ventricle caused by the recoil effect during 
untwisting of the ventricle during the early diastolic filling. In CHAPTER IV we have 
tested this recoil assist device in combination with the support device and presented the 
data to develop a bench-top proof of concept for the biphasic mode of action. 
 
Traditional concepts of heart failure have largely focused on
 
the hemodynamic 
consequences of LV systolic dysfunction. Using
 
a time-dependent model of heart failure, 
it has been proposed
 
that diastolic and systolic heart failure are phenotypic expressions
 
of 
the same disease process that evolves gradually as a continuum
 
of clinical events. Thus 
device designs which address the torsional mechanics
 
may provide superior therapeutic 
advantages as they would provide an better understanding of the pathophysiological 
insights into the mechanism
 
of heart failure; however, this remains inadequately 
addressed in today‘s clinical options for addressing diastolic heart failure .  
 In early stages of cardiac dysfunction, ventricular relaxation either regionally
 
or globally 
becomes abnormally slow and impaired with a progressive
 
loss of the ventricle to 
modulate the timing of onset of relaxation.
 
The epicardial function may remain relatively 
unaffected, and
 
circumferential strain and twist either remains normal or shows
 
exaggerated compensation for preserving the LV systolic performance.
 
Compensatory 
features such as myocardial hypertrophy attempt
 
to reduce subendocardial stress; 
however, such changes are usually
 
maladaptive and detrimental. Furthermore, loss of 
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cardiac
 
muscle resilience also causes progressive delay in LV untwisting.
 
Loss of early 
diastolic longitudinal relaxation and delayed
 
untwisting attenuates LV diastolic 
performance, producing elevation
 
of LV filling pressures. In conclusion we have 
successfully prototyped a diastolic recoil device with adjustable passive chambers to 
modulate end diastolic volume in real time and address the torsional mechanics of the 
heart which has a direct impact on the myocardial energetics.   
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CHAPTER IV 
  
 
DEVELOPMENT OF A COMBINED BIPHASIC SUPPORT &                          
 
RECOIL DEVICE TO FULLY MODULATE DIASTOLIC MECHANICS 
 
Background    
End stage congestive heart failure (CHF) patients represent complex etiologies which 
makes it a daunting challenge to design a single device that not only prevents 
progressive remodeling but then initiates reverse remodeling. There are three factors that 
together come into play during progression of congestive heart failure ---1) failing hearts 
with low cardiac output, 2) failing hearts growing larger, and 3) high filling pressures 
due to loss of recoil preventing complete filling during the diastolic phase of cardiac 
cycle. Presently there are separate device solutions with left ventricular assist devices 
(LVAD), cardiac support devices (CSD) and diastolic recoil devices (DRD) which 
approach these problems individually. A significant unmet need in CHF device 
development is an implantable device which can address both factors of support and 
recoil in a single device design.  
                     
The proposed combined Biphasic support and recoil device is a significant innovation in 
heart failure device space, as it is a fully implantable and minimally invasive device 
under development which can address the issue of cardiac support (passive constraint) 
and diastolic recoil in a single integrated design. The patient population it can serve 
includes patients with either systolic or diastolic heart failure, but also those with 
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combined systolic and diastolic failure. The combination of the cardiac support device 
and the diastolic recoil device (each of which has been prototyped and explained in the 
CHAPTERS II & III) represents an innovation that when deployed into the pericardial 
space surrounding the heart can fully modulate the diastolic mechanics of a failing heart. 
Our bench-top studies have shown that adjustable passive support and diastolic recoil 
technology achieves modulation of end diastolic volume and ventricular filling at low 
end diastolic pressure. Thus we expect this combined device would play a significant 
role in ventricular size reduction and also enhanced ventricular filling in both systolic 
and diastolic heart failure patients. Advancements in novel cardiac device technology are 
needed and toward this end, we have developed a proof of concept of this combined 
device with multiple prototypes tested.  
                                                
Two potential problems with current support technology (i.e., static meshes that 
surround the heart like Acorn‘s CorCap) are: 1) the device cannot be adjusted post 
implantation and 2) support devices may increase chamber stiffness and worsen the 
filling dynamics. Our goal with this device is to evaluate the efficacy of adjustable 
support technology and combined recoil/support technology. Clinical experience has 
been greatest with the Acorn device, which has been shown to reduce end-diastolic 
volume, shear strain, and infarct area in preclinical studies. But there is concern about 
the effect of passive constraint on diastolic LV chamber stiffness and pump function.   
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Study Goals 
Test the hypothesis that combining diastolic recoil enhancement with adjustable cardiac 
support is possible and that such a combination results in a biphasic type support device 
as determined by bench-top studies: In a failing, remodeled heart, passive stiffness and 
slow relaxation time (i.e. diastolic recoil) is often a primary problem, thus an increase in 
diastolic recoil could improve cardiac function. With a combined recoil and support 
device, the EDPVR could be shifted downward for lower volumes and leftward for 
limiting the overall heart size. 
 
Device Design: Biphasic Support & Recoil Device 
The device technology prototyped in this dissertation is designed to fully modulate 
diastolic mechanics and address both systolic and diastolic dysfunction by use of 1) 
adjustable support to limit and/or reverse chamber dilation that contributes to poor 
systolic function and 2) recoil assist to help the heart fill more rapidly during diastole. 
The device has an intrinsic pneumatic attachment to the exterior surface of the heart that 
enables heart motions such as twisting and ejection along with dynamic support. The 
concept of a biphasic support is a fundamental innovation in the field of heart failure 
devices.  
 
The device technology is innovative in four important aspects:  
1. Control of target end-diastolic volume: Our Dynamic Support Device with the 
recoil elements embedded in the frame is the first device that is biphasic about an 
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adjustable ―phase transition point‖ (a target end-diastolic volume, TEDV). As 
shown in Figure 25, for cardiac volumes below TEDV, the device enhances 
filling (i.e., ―filling enhancement‖ phase), and for cardiac volumes above TEDV 
the device impedes filling (i.e., ―filling impediment‖ phase). The adjustability of 
TEDV via infusion of saline in a subQ port will enable ongoing support to 
promote reverse remodeling—i.e., as the diseased heart begins to respond to the 
support by becoming smaller, the TEDV can be adjusted to provide the same 
amount of support as the initial treatment intervention. The ―filling 
enhancement‖ of the biphasic component acts to enhance diastolic recoil. Our 
device has an elastic memory component that is utilized when cardiac pressures 
are lower than TEDV by creating a uniform negative pressure that promotes 
ventricle filling. Diastolic recoil enhancement is potentially critical for effective 
treatment because diastolic heart failure secondary to fibrosis is likely to be 
present in end-stage systolic heart failure. Figure 25 demonstrates the biphasic 
support component of our device. When ventricular volumes are below TEDV 
the device acts to enhance filling and increase ventricular volume, but when 
ventricular volumes exceed TEDV, the device acts to constrain filling and 
cardiac volume.  
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Figure 25. An illustrative plot that demonstrates the biphasic character of the device wherein the 
effect of the device is to impede filling above the transition point (or target end-diastolic volume) 
and enhance filling below the transition point (or target end-diastolic volume). 
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Figure 26. Cross-section of biphasic support and recoil device that depicts the support and recoil 
components. 
 
 
 
2. Combination of recoil and adjustable passive support: Though devices exist with 
specific indications for support, the proposed Biphasic and Dynamic Support 
Device will be the first device which has a dual component of recoil assist and 
adjustable passive support. Adjustable passive support is essential in reducing the 
size of an enlarged heart. Passive support is helpful long term, but likely causes 
acute increases in venous pressure. With the recoil component, this complication 
can be mitigated. The recoil component apart from providing a structural rigidity 
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also acts as a loaded spring which stores energy during the systolic contraction 
and releases the stored potential energy hence increasing the ventricular filling at 
low end diastolic pressure. Figure 26 represents the cross section of the device 
with the dynamic support and recoil component. 
3. Minimally invasive & minimal risk of infection and coagulation: The proposed 
device is a major advancement of heart assist technology that minimizes 
invasiveness, infection, and coagulation and most importantly this device allows 
customization of therapy based on the patient‘s response to the treatment 
strategy. Heart transplant is highly invasive and induces great trauma on the 
patient and complications from anti-rejection medication. The present technology 
incorporates design principles conducive to leading edge minimally invasive 
techniques. The implications of developing this technology will likely extend 
beyond the applications herein. This technology is an excellent candidate for 
combination therapies which combine mechanical, electrical, pharmaceutical, 
and/or stem cell therapies.  
4. Anti-pericardial adhesive barrier: Our Biphasic and Dynamic Support Device 
consists of multiple layers of a biocompatible film with fluid filled bladders 
between the film layers, these prevent trans-thoracic adhesions between the 
epicardial surface of the heart and the chest wall and permit the film layer 
touching the heart to move independently from the film touching the chest wall. 
The inner layer of the device is allowed to form adhesions to the epicardial 
surface of the heart while the outer layer of the device is allowed to form 
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adhesions to the chest cavity. The fluid filled bladder between the two layers acts 
as a barrier preventing adhesions between the epicardial surface of the heart and 
the chest wall.  Not only will this device allow for easier access to the heart in 
case subsequent surgeries are required but it allows the heart to move freely 
inside the chest cavity during normal cardiac contraction. 
 
Bench-Top Proof- of-Concept of Combined Support and Recoil Device 
 
 As can be inferred from the study goals, the entire focus of the bench-top study was to 
obtain EDPVR‘s from a model heart alone and with various components of the proposed 
device in action; thereby allowing comparisons to be drawn between EDPVR‘s in order 
to evaluate the potential effectiveness of each component. 
                  
The project consisted of two phases.  In the first, a heart model was created to mimic the 
EDPVR of a human heart.  A model of the normal heart was chosen because the 
mechanics and response of the normal heart are better known and easier to model than 
the failing heart‘s complicating structural and mechanical alterations, and a model of the 
normal heart is sufficient to meet the goal of demonstrating the device‘s ability to effect 
a bi-phasic modulation of the heart cycle.  This model was used to set baseline values for 
later comparison to the results when the device was tested.  Once a satisfactory model 
was built, the device was tested using the experimental setup described in the remainder 
of the chapter. A flexible alloy frame that compresses during systole and acts to transfer 
energy to the beginning of diastole is placed around the heart, creating a negative 
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pressure in the ventricles that assists recoil and augments ventricular filling.  This frame 
is completely enclosed in a sealed chamber surrounding the heart, filling the dual role of 
preventing fusion to the heart wall and allowing adjustable systolic support. A model of 
the heart was constructed that simulated the EDVPR (end-diastolic pressure-volume 
relationship) of a normal human heart.  The model, shown in Figures 27 and 28, was 
formed by creating a bladder approximately the size of both normal human ventricles.  
The bladder was rigid upon full inflation, thus approximating the shape of the normal 
human heart. Figures 29 and 30 show the device prototypes which were placed on the 
heart model.  
                          
The experimental setup is conceptually simple: pressure or volume was incremented, 
and therefore, known, while the corresponding change in the other variable (volume or 
pressure, respectively) was measured.  The results were then plotted to create an 
EDPVR.  At the outset of the project, volume was used as the independent variable, and 
incrementally increased while the corresponding change in pressure was measured using 
a manometer.  This approach concentrated the readings in the low pressure region of the 
EDPVR, as incremental changes in volume led to major pressure changes as volume 
increased.  Additionally, because a small volume change could create a major change in 
pressure at high volumes, it was difficult to create stable, easily repeatable relationships.  
                     
To avoid these problems, pressure was made the independent variable.  Pressure was 
incrementally changed by varying the difference in height between the model and a 
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water reservoir.  The volume change in the water reservoir corresponding to each 
pressure change was measured, and the results plotted to create an EDPVR.  Figures 31 
and 32 illustrate this setup. The experiment was designed to increment the model‘s 
volume, and measure the corresponding change in pressure.  The results were then 
plotted to create an EDPVR. Pressure was incrementally changed by varying the 
difference in height between the model and a water reservoir.  The volume change in the 
water reservoir corresponding to each pressure change was measured, and the results 
plotted to create an EDPVR.   
 
 
                        
 
Figure 27. Schematic design of the heart model (left) experimental setup with                  
uninflated support device placed on it; (Right) inflated support device placed on the 
model. 
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Figure 28. Cardiac support device (top) Prototype of the model which is used to measure 
EDPVR of a normal heart (bottom) Prototype of the cardiac support device on the heart model. 
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Figure 29. Diastolic recoil device (top) Schematic design of the uninflated diastolic recoil device 
placed on the heart model in the experimental setup; (bottom) Prototype of the diastolic recoil 
device.  
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Figure 30. Diastolic recoil device (top) Schematic design of the inflated diastolic recoil device 
placed on the heart model in the experimental setup; (bottom) Prototype of the diastolic recoil 
device inside the pseudo pericardial sac. 
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Fig 31.  Experimental setup of bench-top study for measuring EDPVR of the biphasic device. 
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Figure 32.  Close-up illustration of heart model, pericardial sac model, and cutaway 
device with diastolic recoil frame and inflated passive support chamber. 
 
 
Pressure readings were taken at 5 cmH2O intervals.  The heart has a normal left 
ventricular end-diastolic pressure of approximately 15 mmHg , or 20 cmH2O; thus, 5cm 
intervals were determined to be sufficient to allow an accurate EDPVR to be obtained. In 
order to obtain an accurate comparison and eliminate as much error as possible, new 
baseline values of the heart model alone were taken at the beginning of every trial.  In 
this experimental setup, the pericardial sac was modeled by a vacuum drawn, as shown 
in Figure 33, in a sac placed around the heart model and device. 
Device in 
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Recoil 
frame 
Pericardial 
sac 
Support 
chamber 
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Figure 33. Device set-up to model a pseudo-pericardial sac. 
 
 
 
Once a baseline EDPVR was obtained, the passive support device was employed without 
the recoil component. Finally, the recoil component was inserted in the passive support 
device (Figure 34). The sets of EDPVRs gained can then be compared and the effects of 
each component – passive support and recoil support – determined. It is important to 
note that the device is not physically secured to the recoil component; therefore, the 
diastolic support component relies on the presence of a vacuum to cause the ventricle 
walls to adhere to the device and follow it outward when it recoils as the heart enters 
diastole.  In the body, the pericardial sac that surrounds the heart provides a vacuum i.e. 
a space without free fluid.   
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Figure 34. Prototype device showing the different components of the biphasic device. Passive 
support component (top) recoil assist component (middle) and combined biphasic device 
(bottom). 
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Figure 35. Prototype device composed of the adjustable support and recoil component. (top) 
Internal surface of the device showing the passive chambers and nitinol frame inside, (bottom) 
complete device with tubings connected to chambers for adjustability. 
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Results
 
To test the ability of a combined recoil/support device  ( Figure 35) to enhance filling at 
low volumes and limit filling at high volumes, we performed a bench-top study using a 
mock heart with a PV relationship that is compliant at low volumes and stiff at higher 
volumes. The device used in the bench-top study was similar to that of the in vivo 
studies, however, we made the nitinol scaffold removable. End-diastolic pressure-
volume relationship (EDPVR), which represents the passive filling mechanics of the left 
ventricle, was obtained in this bench-top study using a mock heart model with recoil 
assist and support device. One of the objectives of the study was to show how the 
device‘s adjustable passive constraint/support component could alter the EDPVR in a 
positive manner and have comparable outcomes with the ovine studies and also exhibit 
recoil effect in addition to adjustable passive support. In the experiment three data runs 
were done, one with heart model only, second passive device with 0ml of water and third 
passive device with 40 ml of water. Figure 36, shows the baseline EDPVR of the heart 
model on the right. The device was then placed on the model with passive support 
chambers unfilled (0mL of water) and an EDPVR was obtained.  In the next data run the 
passive component was filled with 40 mL of water and EDPVR data taken. The EDPVR 
points are plotted in Figure 36. The plots of the EDPVR for the baseline heart model vs 
0mL versus the 40mL show that the EDPVR shifted leftward with gradual decline in end 
diastolic volume. This leftward shift in the EDPVR indicates a decrease in the size of the 
left ventricle relative to filling pressure, i.e. the ventricle maintains the same filling 
pressure at a smaller volume. The downward shift of the EDPVR indicates the enhanced 
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filling being made possible by recoil assist component of the combination device. 
Therefore, bench-top studies have shown that two components i.e. the passive constraint                        
(capable of manipulating the end-diastolic volume) and the recoil assist (augment 
ventricular filling at lower pressures) can make modulation of diastolic mechanics a 
viable goal using a single device.  
 
 
 
Figure 36. Bench-top verification of biphasic support device with a fillable, pseudo-heart 
mimicking the baseline EDPVR. With the device placed on the pseudo-heart inside a sac with air 
evacuated (like the mediastinum) and with the wires maximally tensioned to get the most recoil 
effect, biphasic modulation is evident. 
 
 
 
 
101 
 
Discussion 
 
The results clearly demonstrate the ability of the proposed device to biphasically 
modulate the EDPVR of a model normal heart.  The diastolic recoil frame, the particular 
interest of this study, created substantial negative pressures at low volumes.  This 
pressure drop would lower the filling resistance in ventricles with high stiffness, 
increasing filling volume, decreasing filling time, and ameliorating diastolic dysfunction 
and the associated biochemical responses to it. Also, the constraint of the passive 
systolic support device on maximum filling volumes was also demonstrated in these 
trials, shifting the EDPVR leftward.  This size reduction would prevent overfilling and 
reduce the abnormal stresses on the heart, limiting adverse biochemical cascades and 
inhibiting or even reversing degenerative remodeling and the associated systolic 
dysfunction. 
 
Upon implantation of the device in a live model, several factors will be of special 
interest.  The vacuum sac used in the model maintained a vacuum and had no fluid 
between the device, model and sac.  In vivo, the vacuum in the pericardial sac is 
maintained mechanically post-operatively until the entrance hole in the pericardial sac 
heals.  The pericardial sac is lubricated, which may substantially change the shear 
stresses acting on the device and holding it in place.  In addition to differences in the 
pericardial sac, substantial fibrosis is expected to occur.  The two layer design of the 
device is designed to compensate for this by allowing the pericardium to fibrose to the 
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outside of the device and the myocardium to fibrose to the inside, maintaining the heart‘s 
freedom of movement. 
 
Another factor of interest will be the difference in wall thickness between the left and 
right ventricles.  The model used in this study modeled the two ventricles as a whole, 
with no distinguishment between the left and right ventricles.  It is possible that the 
lower resistance of the right ventricle will absorb a proportionately larger amount of the 
device‘s constraint and recoil, inhibiting right ventricular function and dampening the 
effects on the left ventricle, although a previous unpublished study in sheep of the 
support prototype‘s efficacy did not indicate that this was a significant problem 
(contained in Moreno Thesis currently in publication hold to allow filing of patents). 
 
The two basic components – passive support and diastolic recoil of the biphasic device 
are based on the theoretical foundations of Laplace law (wall stress reduction --- support 
component) and torsional mechanics where potential energy stored during the systole is 
released as a recoiling force when myocardial fibers untwist during diastole. The 
ultimate goal of the device being to initiate the reverse remodeling processes and create 
a normal pattern of systolic and diastolic mechanics leading to a smaller less dilated 
heart. The goal of this device has been to incorporate the design elements which can 
manifest these physical principles and improve upon the devices which are presently in 
different stages of evaluation on the path to final market approval. Table 4 provides a 
comparative analysis of the proposed device and other devices under development, 
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Table 4 Comparison of biphasic support and recoil device with present state of the art 
support and recoil devices 
 
COMPARATIVE 
ANALYSIS 
Proposed 
Device 
Acorn Corassist Paracor 
Device Name: Biphasic device CorCap™  Imcardia 
Paracor 
Heartnet™ 
Type of Product: 
Bridge to 
Recovery 
Destination 
Therapy 
Bridge to 
Recovery 
Destination 
Therapy 
Mode of Assist: 
Passive Support 
& Diastolic 
recoil 
Passive 
Support 
Diastolic 
recoil 
Passive 
Support 
Device 
Adjustability 
Yes No No No 
Promoter of 
Physiological 
Motion 
Yes No No No 
Attachment to 
Heart 
Sutureless, 
pneumatically 
attached 
Requires 
suturing 
Requires 
suturing 
Requires 
suturing 
Risk of Fibrosis Negligible Very High High Very High 
Minimally 
Invasive: 
Yes Yes Yes Yes 
Contact with 
Blood: 
No No No No 
FDA     Approved: 
No, still in 
development 
Human 
Clinical Trials 
Human Pilot 
Trial (Safety) 
Human 
Clinical 
Trials 
Currently on the 
Market (USA): 
No No No No 
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Table 4 continued 
COMPARATIVE 
ANALYSIS 
Proposed 
Device 
Acorn Corassist Paracor 
Currently on the 
Market (Europe): 
No 
Yes, received 
CE marking 
No No 
Length of Time 
Product Remains 
in Patient: 
Minimal: a few 
weeks to a 
month 
Permanent Permanent Permanent 
Device 
Removable: 
Yes 
No ( Redo 
surgeries are 
challenging 
due to 
adhesion) 
No ( Redo 
surgeries are 
challenging) 
No ( Redo 
surgeries 
are 
challenging 
due to 
adhesion) 
 
With use of  Biphasic and Dynamic Support Device,  it is expected to able to continually 
shrink the heart over a period of several months (with 3-4% reduction every 3 weeks), it 
is possible that a diseased heart can be returned to normal size—regardless of the 
etiology. Contractile protein roll-over is ongoing, at a rate of one-half the muscle mass 
per week, and with progressive reduction in end-diastolic volume (EDV), the contractile 
proteins (i.e., end-diastolic sarcomere lengths) may be reset to smaller volumes. 
Reduction of heart size is highly significant because heart size and function are inversely 
related (via the Law of Laplace). We hypothesize, thus, that our Biphasic Dynamic 
Support and Recoil Device will enable proactive intervention whereby specific 
mechanical conditions can be generated and employed to direct growth and remodeling 
processes that are restorative and/or rehabilitative. Our treatment hypothesis to be tested 
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is that an enlarged, dilated heart can gradually be reduced in size without affecting the 
ventricular filling and reducing chamber stiffness.  
 
Conclusion 
 
 The results of the bench-top trials provide in vitro support of the feasibility of 
pneumatic locking as a means for a diastolic recoil device to engaging the heart.  This 
approach avoids the hemo-compatibility issues, among others, encountered by alternate 
methods, and naturally lends itself to a combination with systolic support components 
for a biphasic support/assist device that modulates the entire heart cycle.  Future studies 
would be particularly focused on the limitations pointed out in the discussion where 
pneumatic locking for diastolic recoil devices in vivo would be of interest. 
 
In conclusion we have prototyped and tested the biphasic support and recoil device and 
it successfully fulfills the goals that were set. We have shifted the EDPVR leftward and 
downward showing both support and recoil components effectively contributing to the 
device performance. Thus a proof of concept has been achieved which would need to be 
tested in pivotal preclinical studies. With over six decades of device research for an less 
invasive effective implantable device, today still there are very few FDA approved  
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options for Class III & IV heart failure patients who have mechanical dysfunction of the 
heart. With optimal drug regimen, resynchronization therapies and the present biphasic 
device implanted in a minimally invasive manner and which can contribute to both 
systolic and diastolic performance, we believe would be another option for the patients 
who have a remodeled heart caused by an index event like myocardial infarction. The 
path for Class III devices are long and expensive from bench-top to clinical adaption, but 
with promising bench-top, preclinical acute data and prototype designs we are confident 
further work would be successfully conceived  and performed in future to move it 
towards successful clinical adaption. 
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CHAPTER V 
 
 
ADJUSTABLE CARDIAC DEVICE TO PREVENT                              
PERICARDIAL ADHESIONS AND IMPROVE CARDIAC 
  MOTION IN MULTISTAGE CARDIAC SURGERIES 
 
 
Introduction 
Fibrosis, the formation of excessive amounts of fibrotic or scar tissue is a major problem 
in medicine as scar tissue blocks arteries, immobilizes joints and damages internal 
organs, with serious consequences on the body's ability to perform important roles. 
Every year, about 1.3 million people are hospitalized due to the damaging effects of 
fibrosis with few therapeutic solutions to mitigate the problem. Adhesions are fibrous 
structures that connect tissues or organ surfaces that are not normally joined. They can 
cause significant complications such as bowel obstruction following abdominal surgery, 
infertility following gynecologic surgery, serious complications during secondary 
cardiovascular surgical procedures, restricted limb motion following orthopedic surgery, 
and pain following any surgery. Moreover, adhesions that form as a result of surgery can 
increase the complexity, duration and risk of subsequent surgery. In the United States 
surgeons perform an estimated 500,000 abdominal operations annually to remove 
adhesions.  In the absence of an efficacious means of intervention, the formation of 
adhesions becomes a virtually unavoidable byproduct of the trauma caused to internal 
tissue surfaces during the surgical procedure.   
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Study Goals 
Explore and expand the application of the prototyped cardiac support and recoil device 
as an anti-pericardial adhesion device in pediatric and adult patients undergoing 
multistage cardiac surgery requiring sternotomy. The device features like size 
adjustability and anti-adhesion nature of the fluid filled chambers would allow for 
growing cardiac anatomy in pediatric patients and also allow for finding the surgical 
plane during repeat sternotomies. In addition to these features the basic device features 
like anatomical compatibility and ventricular support would improve the overall cardiac 
performance of the patients. 
 
Background 
One of the most important pathologies for which fibrosis is a problematic factor is 
cardiac surgery. The number of patients undergoing cardiac surgery has been steadily 
increasing, and as a consequence, the number of cardiac reoperations has also increased 
[105-111]. It has been estimated that one out of every five patients undergoing coronary 
artery bypass surgery will require a reoperation [107, 108]. Re-operative cardiac surgical 
procedures are associated with a significantly greater complication rate than that of the 
initial procedure [110, 111]. For example, the post-operative complication rate following 
a reoperative coronary artery bypass procedure nearly doubles. As a consequence, 
cardiac reoperations are associated with increased morbidity and mortality [106-111]. 
An important contributory factor for the increased complications with cardiac 
reoperations is the adhesions which form secondarily from the initial entry into the 
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pericardium [105-111]. These fibrous adhesions begin to form immediately following 
the surgical procedure and consist of collagen and other extra cellular proteins [112, 
113]. It has been demonstrated in a number of cell systems that enhanced collagen 
synthesis can occur due to increased production of angiotensin II (Ang II) and 
subsequent activation of the Ang AT1 receptors [114-116]. The post-operative period 
following cardiac surgery is associated with heightened neurohormonal stimulation, 
which in turn could potentially contribute to pericardial adhesion formation [117]. 
 
Adhesion formation after open-heart surgical procedures is a significant complication at 
the point of performing a secondary procedure.  It is estimated that secondary procedures 
(re-do‘s) account for 15-20% of the approximately 425,000 open-heart surgeries 
performed annually in the United States.  Extensive adhesions form between the surface 
of the heart (epicardium) and the inner surface of the sternum after virtually every open-
heart surgical procedure.  These adhesions make opening the sternum and accessing the 
heart a time consuming and dangerous process in the secondary procedure.   
                   
Recently a large number of patients with congenital heart defects
 
have required repeat 
sternotomy because reoperations and staged
 
surgical procedures are increasing. Repeat 
sternotomy and dissections
 
carry a risk of further reoperation because mediastinal 
adhesion
 
formation may result in iatrogenic injury of the heart, arteries,
 
or veins. In 
addition, mediastinal adhesions make it difficult
 
for surgeons to identify anatomical 
features, prolong the operating
 
time for dissections, and increase blood transfusion 
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requirements. Closure of the pericardium is one of the strategies to prevent
 
these 
drawbacks. However, pericardial closure is usually impossible
 
because it may cause 
cardiac tamponade or late constriction
 
after surgery. Moreover, in a 2
nd
 or 3
rd
 repeat 
sternotomy,
 
there remains no pericardium available for chest closure. So
 
far, various 
materials, such as silicone rubber, polyurethane,
 
fascia lata, expanded 
polytetrafluoroethylene (ePTFE), heterologous
  
porcine, equine, or bovine pericardium, 
Dacron, and dura mater
 
have been employed as pericardial substitutes to secure safer
 
resternotomy. The widely used ePTFE sheet is reported
 
to be safe and effective in 
preventing cardiac injury at resternotomy. However, such nonabsorbable material might 
cause dense adhesions
 
and severe inflammatory reactions including fibrotic change,
 
calcification, and mediastinitis after implantation.
 
An
 
ideal pericardial substitute to 
prevent these drawbacks in reoperations
 
is required, especially in the field of pediatric 
cardiac surgery
 
where multistage operations are often needed. 
 
Present Anti- Pericardial Adhesion Devices 
There are multiple anti pericardial adhesion products in market which are FDA approved 
and also off label use of these materials. Some of the products in clinical use today are 
Interceed® (Johnson & Johnson), Seprafilm® (Genzyme), CoSeal® (Angiotech 
Pharmaceuticals, Inc.), and Adept® (ML Labs Ltd.), both licensed in certain markets to 
Baxter International, CardioWrap® (Mast Surgical),and licensed, in certain markets, to 
CryoLife and Preclude® (WL Gore).  Several other companies including, Anika 
Therapeutics, Inc., Alliance Pharmaceuticals, Corp., Covidien, Integra Life Sciences, 
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Inc. and Fziomed, Inc. are pursuing the development of products for the prevention of 
adhesions. The anti-adhesion market is characterized by a limited number of products 
currently on the market with limited (as a percent of total surgical procedures using such 
products) penetration with key differentiators being clinical efficacy, biocompatibility, 
ease of use and price. 
 
Adjustable Device Solution to Prevent Pericardial Adhesion 
The adjustable support device prototyped here can function as a contoured pericardial 
adhesion barrier device that reduces pericardial adhesions between the epicardial surface 
of the heart and the chest wall after a sternotomy or cardiac procedure. The pericardial 
adhesion barrier device does not need to be sutured or directly attached to the heart. 
Rather, the pericardial adhesion barrier device intrinsically attaches to the heart via 
pneumatic locking. There is no free air in the chest to go between the device and heart—
so if the heart becomes smaller (due to ejection of blood), the device must be pulled 
inward. Likewise, when the device pushes outward, it applies a suction-like traction to 
the heart. If free air were present in the chest (it is normally not) the suction-like traction 
would draw air to come between the device and heart. However, with no free air, the 
suction traction is applied directly to the heart surface. After air in the mediastinum is 
removed, the heart and device are pneumatically locked in a co-axial configuration.  
                          
The pericardial adhesion barrier device, as shown in Figure 37, consists of at least two 
layers of a biocompatible film and a fluid filled bladder between the two layers which 
112 
 
prevents and/or reduces postoperative pericardial adhesions between the epicardial 
surface of the heart and the chest wall.  The bladders within the pericardial adhesion 
barrier can be used to correct end diastolic and end systolic configurations of a damaged 
or diseased heart. The bladders of the pericardial adhesion barrier device may also be 
used to assist a damaged or diseased heart in cardiac output and motion without 
significantly perturbing the physiological shape of the heart. Many patients that undergo 
cardiac surgery must have multiple reoperative procedures, including repeat 
sternotomies. The device reduces postoperative adhesions making subsequent surgeries 
easier to perform. The device is implanted after a sternotomy around at least a portion of 
the heart to accommodate the lack of a complete pericardium due to cardiac surgery. The 
inner layer of the pericardial adhesion barrier device is allowed to form adhesions to the 
epicardial surface of the heart while the outer layer of the device is allowed to form 
adhesions to the chest cavity. The fluid filled bladder between the two layers acts as a 
barrier preventing adhesions between the epicardial surface of the heart and the chest 
wall.  Not only will this device allow for easier access to the heart for subsequent 
surgeries but it will also allow the heart to move freely inside the chest cavity during 
normal cardiac function. The pericardial adhesion barrier device can also be used to 
adjustably control the end diastolic shape of the heart, actively control the end systolic 
shape of the heart, and assist in normal cardiac function via diastolic recoil capabilities 
and direct cardiac compression for various cardiac pathologies.  
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Figure 37. Two layers of a biocompatible film and a fluid filled bladder without the recoil 
elements, between the two layers; the device prevents and/or reduces postoperative pericardial 
adhesions between the epicardial surface of the heart and the chest wall. 
 
 
The pericardial adhesion barrier device described in Figure 38 uses the intrinsic 
pneumatic attachment and its elastic properties to enhance the diastolic recoil of the 
heart. At the end of systole and the beginning of diastole the pericardial adhesion barrier 
device acts like a loaded spring, applying negative pressure to the exterior epicardial 
surface of the heart, helping the ventricles of the heart to fill. 
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Figure 38. Two layers of a biocompatible film and a fluid filled bladder with the recoil elements 
between the two layers; the device prevents and/or reduces postoperative pericardial adhesions 
between the epicardial surface of the heart and the chest wall. This device not only creates a 
recoil effect with better filing and also has the tubing connected to subcutaneous port which is 
used to modulate the device size with the changes in cardiac dimensions primarily in pediatric 
patients. 
 
 
The device includes a selectively inflatable end-systolic heart shaped bladder with one or 
more contoured supports configured to surround at least a portion of the heart to provide 
curvatures similar to the proper shape of the heart when pressurized and one or more 
fluid connections in communication with the selectively inflatable end-systolic heart 
shape bladder for pressurization and depressurization. The contoured supports form 
inflatable compartments having an expanded curvature optimized to fit generally the 
proper end-systolic shape of the heart.  The selectively inflatable end-systolic heart 
shaped bladder comprises an inner membrane that is at least partially folded when 
depressurized and at least partially unfolds when pressurized.   
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Important Features of the Device 
 
The device prototyped here when supported by a good surgical technique is expected to 
decrease significantly post-surgical adhesions. The benefits are following: 
1. Making redo surgery safer:  
a. making the surgical procedure easier and also less painful, 
b. lowering the time of procedure (and anesthesia), 
c. limiting other clinical risks 
2. Biphasic device adds minimal time to the overall procedure as it conforms to the 
cardiac anatomy and does not require suturing as its anchors to heart through 
pneumatic attachment.  
3. Full view of the surgical site as the device is made of transparent film that does not 
impede the surgeon's full view of the surgical site during or after application, 
allowing visualization of key anatomical landmarks for safe and optimal placement. 
4. Biocompatible as the polymer materials used in biphasic device have been used in 
numerous other medical implants and are well recognized as safe and biocompatible. 
5. Easy access to surgical plane hence reduced risks associated with sternal re-entry and 
dissection of post-operative cardiac adhesions which expose the patient to critical 
risks and significantly higher complication rates, hence reduced risk of severe 
hemorrhage with significant morbidity and mortality 
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Conclusion 
 
In conclusion we have explored a new application of the cardiac device prototyped here 
which can be applicable as an anti-pericardial adhesion device. The device would 
significantly benefit both pediatric and adult patients undergoing cardiothoracic 
surgeries with clinical indications needing multiple sternal entries. Presently all anti 
adhesion options are materials which are available as films which needs to be surgically 
fitted after the vascular or cardiac surgery is completed. This anti adhesion device 
solution would be first in class that also functions as a device, which apart from 
preventing pericardial adhesion post surgically can modulate diastolic mechanics with an 
adjustable feature to optimize the device size allowing for changes in cardiac anatomy. 
Pediatric patients can benefit immensely from this as their cardiac anatomy undergoes 
rapid growth. Thus a novel device solution has been proposed with next steps being 
preclinical evaluation in large animal models. 
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CHAPTER VI 
 
CONCLUSION & FUTURE WORK 
 
Conclusion 
The present critical gap in the development of non blood contacting cardiac support 
devices for both systolic and diastolic dysfunctions is a device solution that can 
concurrently modulate diastolic mechanics to improve ventricular filling while providing 
a passive constraint to prevent ventricular dilatation. An approach that can address the 
dual aspects of improved filling and effective passive support to induce reverse 
remodeling would be a major improvement over present solutions. 
 
Passive constraint devices seeking FDA approval like Paracor Heartnet and the Acorn 
CorCap fabric ―jacket‖, and experimental ones the fluid-filled balloon described by 
Ghanta and colleagues are presently developing non blood contacting approaches to 
prevent ventricular dilatation. Experience has been greatest with the Acorn device, 
which has been shown to reduce end-diastolic volume and, shear strain, and infarct area 
in preclinical studies. On the other hand, there has been concern about the effect of 
passive constraint on diastolic LV chamber stiffness and pump function. In this 
dissertation we have discussed a novel device approach that features a biphasic, 
dynamically adjustable cardiac support device with recoil elements in a single integrated 
design. This device is designed to address both systolic and diastolic dysfunction by 
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being uniquely able to provide a tunable constraint compared to deleterious acute impact 
of a passive girdle.  
 
In this project we have tested the hypothesis that adjustable cardiac support in 
conjunction with a recoil feature can be combined to modulate the diastolic mechanics 
leading to improved early diastolic filling while limiting the overall heart size. It is 
expected that this would have a significant impact on the both therapeutic approaches 
involving passive constraint devices for patients with systolic heart failure and also in 
diastolic heart failure where passive elastic properties are impacted. As heart size returns 
to normal we hypothesize that cardiac function will improve, at a minimum because of 
Law of Laplace effects (i.e., as heart diameter decreases the myocardium gains 
mechanical advantage and performs better) and possibly because of recovery of the 
myocardium. We further hypothesize that cardiac function can be improved acutely 
during the progressive support regimen with the use of recoil; and moreover, that the 
combination of support and recoil can potentially lead to much greater improvement 
because two separate characteristics of CHF are addressed, systolic and diastolic 
dysfunction respectively. We have performed studies with our prototypes to test the 
following objectives: 
A. Test the hypothesis that adjustable cardiac support can be employed to left shift 
the End-diastolic pressure Volume Relationship. The end-diastolic pressure–
volume relationship (EDPVR) is one of the most important means of 
characterizing the passive ventricular properties of an individual heart. In 
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particular, the EDPVR indicates the physiologic determinant of preload by 
indicating the amount of diastolic filling that will occur for a specified filling 
pressure.  
B. Test the hypothesis that combining diastolic recoil with adjustable cardiac 
support would limit heart size without constraining the early diastolic filling. In a 
failing heart passive stiffness and slow relaxation time i.e. diastolic recoil is a 
primary problem in remodeled hearts, and thus an increase in recoil could 
improve cardiac function without impeding the filling during diastole. The 
EDPVR measurement would be used to quantify this specific aim. 
 
The biphasic dynamic support and recoil prototype device discussed in this 
dissertation is being developed to address a vast unmet need of a minimally invasive 
implantable device solution to reverse LV remodeling (ventricular size) and 
concurrently reduce the ventricular filling pressure in patients with end stage heart 
failure. We have prototyped and tested a novel device technology which fully 
modulates diastolic mechanics in two principle ways (1) adjustable passive cardiac 
support or progressive constraint to facilitate the gradual reduction in size of dilated, 
diseased hearts, thereby improving pumping efficiency; (2) diastolic recoil 
technology with the ability to transfer energy from systolic contraction to diastolic 
filling, which may potentially reduce ventricular filling pressures, without 
compromising ventricular systolic function. 
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As for any new technology there are risks which are being addressed from early stages to 
clinical introduction as the design iterations are being implemented at each stage of 
development from bench-top to completion of human trial.  The technical risks of this 
technology are both treatment specific and device specific. Overcoming these barriers is 
key to curing heart failure. The risk is considered high at this early stage with limited 
preclinical data about how this intervention will affect the biological remodeling and 
repair processes in the heart. These barriers are surmountable as rudimentary 
implantation methods and device adjustment methods are already working, and human 
clinical studies will require somewhat modified approaches from those used with 
animals as we undergo multiple iterations and feedback analysis. Once we complete the 
proposed design work, make transition to GMP processes and obtain efficacy data, 
funding will be sought to develop solutions to barriers for moving to clinical adaption. 
The risks and feasibility are divided into two subparts below: device specific risk and 
treatment specific risk. 
                      
Device specific risk: Being classified as a possible class III implantable device, the 
proposed device definitely has high design risks as there are with developing an 
implantable device which would be placed inside the pericardial sac and having the 
device be deployed in a minimally invasive manner. The passive cardiac support devices 
are in development over 15 years and there has been no significant safety issue of these 
devices as they have been in clinical trials for over 10 years. But as of today these 
devices have yet to penetrate the market place as an approved device. Corcap from 
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Acorn Cardiovascular and Heartnet from Paracor Medical are the devices closest to 
market and would open up a completely new therapeutic option for patients with end 
stage heart failure. The indications of these devices might be expanded in future as an 
intervention post acute myocardial infarction to stabilize the myocardium.  
                      
With implantable devices, biocompatibility and sterilization are obvious risks which are 
primarily addressed with appropriate choice of materials and sterilization method. The 
most technically difficult aspect of safety then, is in mitigating device failure over a 
period of time. Living tissues are constantly repairing broken fibers and other 
microstructural defects whereas implantable devices accumulate damage. Given the 
loading of the cardiac device at a constant pressure, the device construction has to meet 
very high standards of quality and mechanical testing.  Devices that appear simple from 
engineering standpoint on the bench-top can be grand technological innovations when 
designed for implantation. Moreover, the risk associated with the procedure to achieve 
implantation can be so great, that implanting the device is simply not an option for some 
portion of the patient population. Therefore, leading edge minimally invasive 
deployment techniques are preferred. This requires substantial innovation in the design 
of the device and its deployment technique, as the device must transform from one that 
is collapsed or compacted for minimally invasive delivery to one that is reconstituted 
and functions completely as intended after deployment. With the exception of aortic 
balloon pumps, heart assist and support devices are not implantable in a minimally 
invasive manner. In summary, device interaction with the heart is intrinsically high risk 
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because of known unknowns and many unknown unknowns. There is always a 
substantial technological risk and failure mitigation comes from many cycles of 
prototyping, testing, evaluating failures, and redesigning.  
                       
Treatment specific risk: Technology that fully modulates diastolic mechanics in a 
minimally invasive way is not available today as a device option; hence the benefits and 
complications of the proposed intervention are mostly unknown. Though the proposed 
technology is well founded on sound scientific principles and evidence from studies of 
mechanobiology in the literature, it is entirely possible that there will be new findings on 
the device design side.  Wall stress, electrical depolarization, calcium handling, oxygen 
utilization, reversion to fetal myosin isoforms, and many other phenomena have been 
implicated in end stage CHF and other structural cardiomyopathies. These may be 
secondary to kinematical etiologies, yet it is possible that some and perhaps all may be 
primary contributors that are more important than the end diastolic and end systolic 
configurations that this device will modulate. Well-designed, scientific long term animal 
studies are needed to assess the proposed treatment effectiveness. Multiple design cycles 
of prototyping, testing, evaluating failures, and redesigning have been conducted, and 
the latest prototypes demonstrate the necessary capabilities. In addition, we have 
developed and tested strategies for mitigating possible failures of the device. In a passive 
mode of operation we believe there will be a minimal chance of any restriction of normal 
cardiac function triggered by any operational functioning of the device.  
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The biphasic device is expected to inhibit the remodeling processes or progressive 
enlargement associated with advancing disease.  Given that contractile proteins in the 
heart are in a constant state of flux with absorption and formation occurring 
simultaneously—at rates equal to approximately half of the heart muscle mass per week, 
it is hypothesized that with an adjustable cardiac support device it may be possible to not 
only inhibit enlargement but to stimulate reverse-remodeling processes with 
incrementally smaller diameters. Preclinical and clinical evidence from multiple studies 
done with Corcap (Acorn Cardiovascular) and Heartnet (Paracor Medical) device shows 
that it might be possible that the same device could prove efficacious in early 
intervention post acute myocardial infarction to stabilize the myocardium and limit 
infarct expansion. The device developed is also applicable in reducing pericardial 
adhesion in multi-stage cardiothoracic surgeries in pediatric and adult patients. 
                    
In conclusion, the proposed adjustable support device with assist and recoil capabilities 
would provide an integrated approach to treating CHF whereby the therapeutic target is 
improving global cardiac function. As the essential first step toward that end, we need to 
investigate the benefits of adjustable passive support with and without diastolic recoil. It 
is hypothesized that adjustable passive support combined with diastolic recoil will 
provide the best device based therapeutic option in the treatment of end stage heart 
failure and that reverse remodeling processes may be stimulated by such an intervention 
thereby providing the foundation for a therapeutic regimen targeting cardiac 
rehabilitation and a viable alternative to transplant therapy. The device does not contact 
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the blood, can be delivered via minimally invasive procedures, and is held in place by an 
intrinsic pneumatic attachment (i.e. does not require suturing to the heart). Specifically, 
we are developing a technology that will (1) provide adjustable passive cardiac support 
and constraint by controlling the target end-diastolic volume which is designed to 
facilitate the gradual reduction in size of hypertrophied diseased hearts and enhance 
diastolic recoil, thereby improving pumping efficiency; (2) provide recoil assist designed 
to reduce chamber stiffness and increase ventricular filling (3) be deployable via 
minimally invasive procedures; and (4) create a fluid filled barrier between the heart and 
chest wall to prevent trans-thoracic adhesions and improve cardiac motion. Thus 
combining passive support and recoil capabilities may lead to greater improvement 
because two separate indications of CHF are addressed, systolic and diastolic failure 
respectively. Our preliminary studies demonstrate that our device is safe and operates as 
intended. We now need to examine the effectiveness of such a comprehensive device 
based therapy in the treatment of CHF.  
 
Future Work 
The present work has been conducted to bring a novel device idea to proof of concept 
and there exists a long road ahead to take it from preclinical to clinical stages following 
the path of FDA approval. From historical analysis of FDA‘s regulatory guidance on 
similar class of devices for treating end stage heart failure, this device would be 
categorized as a Class III device and going by the complexity and resources needed to 
take this device forward it would require multiple sources of funding from both 
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academic and commercial routes. In the sections below we discuss the proposed efficacy 
studies and the path to commercialization, as the real benefit of this project would be 
realized when this device can be successfully implanted in a patient in a clinical setting 
with positive clinical outcome. 
 
Preclinical evaluation: Efficacy study  
The efficacy study is designed to evaluate the effectiveness of the novel cardiac support 
device with recoil elements to fully modulate the diastolic mechanics and reverse the 
ventricular remodeling leading to better understanding of mechanisms of heart failure 
progression and recovery. The goal of the study, as shown in the preclinical study design 
in Figure 39, would be to develop a clear understanding of the contribution of recoil and 
adjustability to passive support devices. Towards that goal, five groups each comprising 
of five sheeps with the same model of heart failure (LAD occlusion) would be studied. 
All the groups will be monitored for 8 weeks after induction of Myocardial Infarction 
(MI) for postoperative recovery and then randomized into five different groups.  
 
The five groups would be followed for 16 weeks until a terminal study (earlier if 
complications arise). The groups have differing device interventions as follows: 
 
1. SHAM (MI + No device, n=5): This group would have the device being implanted 
and removed .Group will be monitored for the same period as treated groups (16 
weeks post MI) and undergo the same terminal procedure with pathology evaluation. 
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2. FXDCSD (MI + Fixed support device, n=5): At 8 weeks post MI, this group will be 
implanted with a device that surrounds the heart; however, the device will not be 
adjusted. The device would be like a fixed or non-adjustable CSD, such CorCap or 
HeartNet. Hence, this group is referred to as the fixed CSD group.  
 
3. ADJCSD (MI + Adjustable support device, n=5): At 8 weeks post MI, this group 
will be implanted with an adjustable CSD that can be progressively tightened with 
infusion of saline in a subQ injection port. With 12 adjustments (one per wk), the 
size of the heart will be progressively constrained. 
 
4. REC+FXDCSD (MI + Fixed support device with Recoil elements, n=5): At 8 weeks 
post MI, this group will be implanted with a CSD adjusted similar to ADJCSD, 
however, the device will also have recoil elements embedded in it to obtain 10 
cmH20 suction at end-systolic volume. 
 
5. REC+ADJCSD (MI + Adjustable support device with Recoil elements, n=5): At 8 
weeks post MI, this group will be implanted with a CSD adjusted similar to 
ADJCSD, however, the device will also have recoil elements embedded in it to 
obtain 10 cmH20 suction at end-systolic volume. 
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Data Collection time points: 
1. BASELINE (BASE): 0 weeks, Data collected prior to induction of CHF 
2. PRETREATMENT (PRE): 8th Week: Data collected prior to randomization and 
device implantation 
3. POSTREATMENT (POST): 16th Week: Data collected at terminal evaluation          
                               
       
 
 
 
        
 
 
 
 
       
 
       
 
      (BASE)                                 (PRE)                                                                     (POST) 
      0 Week                              8
th
 week                                                                           16
th
 week 
     
 
Figure 39. Summary of chronic preclinical study design. 
 
 
In this project we will test three hypotheses:  
1. Adjustable cardiac support is more effective than fixed (i.e., non-adjustable) 
cardiac support,  
2. Combination of recoil assist with fixed cardiac support is more effective than 
only fixed cardiac support, and  
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3. Benefits of adjustable cardiac support and recoil assist are additive because they 
target separate mechanisms.  
 
The technology developed here is not ready for clinical use; yet, the scientific question 
here is critical to the development of the next generation of support technology—i.e., 
can recoil assist and/or adjustability increase the efficacy of cardiac support. Toward this 
end, this novel device technology is ideal because with the same device profile, with the 
same surface area of interaction with the heart, and with the same implantation 
procedure we can deliver the four different devices needed. 
 
From preclinical to clinical path 
 
The research conducted over last five years leading to the device discussed in this 
dissertation, has been developed keeping in mind the FDA‘s concept of ―critical path 
initiative‖. The FDA critical path involves design and manufacturing according to GMP 
regulations, preclinical animal studies following GLP regulations and clinical trials 
utilizing GCP regulations. (GMP stands for ―Good Manufacturing Practice‖, GLP stands 
for ―Good Laboratory Practice‖, and GCP stands for ―Good Clinical Practice‖.) It is 
understood that advancement along the critical path is a serial progression with design 
constraints and choice of materials mapping to manufacturing processes and to animal 
testing requirements with animal study outcomes mapping to clinical trial design and 
disclosure of potential risks. Ideally, device development progresses from manufacturing 
to animal studies and then to clinical trial. An investigation device exemption (IDE) for 
clinical trials requires manufacturing characterization and animal study data. Our 
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approach is as per FDA recommendations with implementation of a quality system for 
design and manufacturing, followed by a pre-IDE meeting with FDA to outline 
requirements for preclinical animal studies and clinical trial design. This approach is 
detailed below with plans to reach six milestones. 
Regulatory Milestones: 
1. Develop design controls and quality systems regulation for the development of 
Biphasic Support & Recoil Device. The next step in the commercialization of the 
biphasic cardiac device is to develop and implement quality systems regulation 
(QSR) with design controls—a necessary component of GMP. The QSR will be 
designed, implemented, and evaluated based on the criteria discussed in the Design 
Control Guidance for Medical Device Manufacturers, which are guidelines set forth 
by the FDA. This technical objective will be completed when satisfactory QSR and 
design controls are in place for evaluating the design development of cardiac support 
devices and minimally invasive deployment fixtures. In short, to move forward on a 
path toward clinical introduction of this technology it is imperative that QSR be 
implemented. Briefly, design guidelines are focused on the following: design and 
development planning, design input, design output, design review, design 
verification, design validation, design transfer, design changes, and design history 
file. 
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The development process shown in figure 40 below is an example of a waterfall 
model based on FDA guidance. In the development process, requirements or design 
inputs are determined from user needs and a design process is used to meet those 
requirements. When the design input has been reviewed and the design input 
requirements are approved, an iterative process of translating those requirements into 
a device design begins. The design process phase involves the conversion of design 
input requirements into system specifications, which become design output. The 
design output is then evaluated through the verification process and the result 
becomes the design input for the next step in the design process, and so on.  
 
 
 
Figure 40: Design development process shown is an example of a waterfall model. 
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Once all of the design inputs have been processed and design outputs have been verified 
then the outputs are transferred to production. Feedback paths are required between each 
phase of the process and previous phase to ensure that there is cohesion between phases. 
Design reviews are conducted at strategic points in the design process. An example of a 
design review includes assuring design input requirements are adequate before they are 
converted to design specifications. Basically, design reviews are used to verify that an 
activity or phase has been completed effectively before moving on to the next activity or 
phase. The final step in the waterfall model is validation, which encompass verification 
and extends the assessment to address whether the device produced meets the 
requirements and expectations of its intended use.  
2. Employ the design controls and quality systems regulation developed to produce 
functional prototypes, ―freeze‖ the design, and complete a pilot production run. 
Presently, all devices are made by hand using off-the-shelf materials and supplies. 
The hand-made devices have enabled completion of proof-of-concept and safety 
studies. The design of the device and delivery systems must now be optimized for 
manufacturing without loss of performance. Once an appropriate design has been 
developed using the design controls and quality systems regulation, pre-pilot and 
pilot production run will be executed. All devices and delivery systems produced in 
this run will be validated using appropriate bench-top tests as identified in the design 
process.  
3. Conduct pre-IDE meeting with FDA: Given the need to assure high quality in the 
design, manufacture, and usage of class III medical devices, meetings with FDA 
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would be conducted to achieve a common goal of safety and efficacy. Once the 
design features and material characteristics are defined, preclinical animal studies 
plan and clinical trial design would be discussed in pre-IDE meeting with FDA.  
4. Perform preclinical animal studies as per pre-IDE meeting with FDA: Once the 
device is manufactured using the  legacy materials with a known toxicity profile 
animal safety studies are expected to be focused on adjustability of cardiac support 
(16 weeks), safety of biphasic support (16 weeks), and cardioprotective capabilities 
(buffering of heart in fluid filled space with lack of fibrous adhesions of heart to 
chest wall). 
5. Design clinical trial as per pre-IDE meeting with FDA: Clinical trials for cardiac 
support devices (bridge-to-transplant and destination therapy) as well as for support 
devices (Cor-cap) have been designed, approved by FDA, and published. In such 
trials, the device would need to show usefulness of the support and recoil technology 
for inducing and sustaining heart recovery 
6. Obtain Investigation Device Exemption (IDE) from FDA to begin clinical trials: One 
of the major milestones in the design and development stage before reaching human 
trials is submission of IDE application to FDA and approval of IDE to begin clinical 
trials.  
7. Complete clinical trials and initiate statistical analysis.  
Table 5 provides a path to final product design, GMP manufacturing and market roll-out.   
 
 
133 
 
Table 5 Proposed commercialization path of the device from concept to market 
 
Phase 
 
Expected Milestones 
Phase I 
 
 
1. Fabrication of  prototype device for animal studies 
2. Successful implantation of recoil and adjustable cardiac support 
device , in an ovine CHF model, in a minimally invasive manner 
via a minimally invasive, one-inch long sub-xiphoid incision 
3. Acute reduction of end-diastolic diameter of the end-diastolic 
diameter by 3-5% without compromising cardiac output in an 
ovine CHF model. 
4. Pre IDE meeting with FDA to develop a strategy for a 
publishable preclinical study and possible designs of pilot and 
pivotal clinical trials. 
 
Phase II 
 
 
1. Design and fabrication of prototype for pivotal preclinical studies 
2. Assess the treatment effectiveness of an adjustable cardiac 
support device with for an ovine CHF model as compared to 
conventional (e.g., CorCap) and to best medical management 
3. Implementation of Quality System Regulations (QSR) 
4. Manufacturing Systems Auditing - ISO 9000 & CE 
5. Assess the treatment effectiveness of a recoil and adjustable 
cardiac support device for an ovine CHF model as compared to 
adjustable CSD and conventional CSD, and to best medical 
management. 
 
Phase III A 
 
 
1. Design of prototype device for pilot human clinical trials. 
2. Selection of GMP-qualified manufacturer, & fabrication of 
prototypes for Clinical Trials. 
3. Investigational Device Exemption (IDE) Application to FDA for 
conducting Clinical Trials. 
4. Identify site for and obtain IRB Approvals for clinical trials. 
(Likely source is Texas Heart Institute). 
5. Identify Contract Research Organizations (CRO) for initiating 
global clinical trials. 
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Table 5 continued 
 
Phase 
 
Expected Milestones 
Phase III B 
 
 
1. Initiation of a Randomized Multisite Clinical Trial in US, and 
globally. 
2. Continuous Design Feedback from user group and working with 
the regulatory agencies. 
 
 
Phase IV 
 
 
1. Achievement of Premarket Approval (PMA) Application from 
FDA  & also European, Asian, Canadian Regulatory Agencies 
2. Negotiation with regulatory agencies regarding any requirements 
or changes in the Clinical Trial & Quality Systems Design 
Reviews 
3. Negotiation with Medicare on Reimbursement issues 
4. Implementation of Customer support, sales/marketing, and service 
functions 
5. Acquisition, sales or selective licensing of technology to strategic 
corporate partners 
 
 
While effective pharmacologic therapies
 
have improved outcomes for mild-moderate 
heart failure, the potential impact
 
of newer therapies and minimally invasive mechanical 
circulatory support for advanced
 
heart failure has not yet been realized. Though 
implantable devices have
 
been shown to be safe and effective, further work is needed to  
realize the full potential of mechanical support and recoil in the treatment and  
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maintenance of CHF as well as the possibility of stimulating ventricular recovery and 
cardiac rehabilitation. Results of adjustable support devices are encouraging and support 
our hypothesis that such devices can be employed to reverse remodel the heart. 
However, the combination of support and recoil will enable a complete modulation of 
the mechanical environment of the heart to guide remodeling processes. Given the 
mechanical nature of cardiac function, the role of mechanics in cardiac development and 
the role of mechanics in the progression of heart failure, it is reasonable to expect that 
therapies that enable the manipulation of mechanical factors about the heart may provide 
essential modes of therapeutic intervention that could be vitally beneficial to patients 
with congestive heart failure.  
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